Published in final edited form as:

Int Rev Neurobiol. 2019 ; 148: 169–230. doi:10.1016/bs.irm.2019.10.017.

Alcohol drinking exacerbates neural and behavioral pathology in the 3xTg-AD mouse model of Alzheimer's disease

Jessica L. Hoffman[†], Sara Faccidomo[†], Michelle Kim, Seth M. Taylor, Abigail E. Agoglia, Ashley M. May, Evan N. Smith, L.C. Wong, Clyde W. Hodge^{*}

Department of Psychiatry, Center for Alcohol Studies, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that represents the most common cause of dementia in the United States. Although the link between alcohol use and AD has been studied, preclinical research has potential to elucidate neurobiological mechanisms that underlie this interaction. This study was designed to test the hypothesis that nondependent alcohol drinking exacerbates the onset and magnitude of AD-like neural and behavioral pathology. We first evaluated the impact of voluntary 24-h, two-bottle choice home-cage alcohol drinking on the prefrontal cortex and amygdala neuroproteome in C57BL/6J mice and found a striking association between alcohol drinking and AD-like pathology. Bioinformatics identified the AD-associated proteins MAPT (Tau), amyloid beta precursor protein (APP), and presenilin-1 (PSEN-1) as the main modulators of alcohol-sensitive protein networks that included AD-related proteins that regulate energy metabolism (ATP5D, HK1, AK1, PGAM1, CKB), cytoskeletal development (BASP1, CAP1, DPYSL2 [CRMP2], ALDOA, TUBA1A, CFL2, ACTG1), cellular/oxidative stress (HSPA5, HSPA8, ENO1, ENO2), and DNA regulation (PURA, YWHAZ). To address the impact of alcohol drinking on AD, studies were conducted using 3xTg-AD mice that express human MAPT, APP, and PSEN-1 transgenes and develop AD-like brain and behavioral pathology. 3xTg-AD and wild-type mice consumed alcohol or saccharin for 4 months. Behavioral tests were administered during a 1-month alcohol-free period. Alcohol intake induced AD-like behavioral pathologies in 3xTg-AD mice including impaired spatial memory in the Morris Water Maze, diminished sensorimotor gating as measured by prepulse inhibition, and exacerbated conditioned fear. Multiplex immunoassay conducted on brain lysates showed that alcohol drinking upregulated primary markers of AD pathology in 3xTg-AD mice: A β 42/40 ratio in the lateral entorhinal and prefrontal cortex and total Tau expression in the lateral entorhinal cortex, medial prefrontal cortex, and amygdala at 1-month post alcohol exposure. Immunocytochemistry showed that alcohol use upregulated expression of pTau (Ser199/Ser202) in the hippocampus, which is consistent with late-stage AD. According to the NIA-AA Research Framework, these results suggest that alcohol use is associated with Alzheimer's pathology. Results also showed that alcohol use was associated with a general reduction in Akt/mTOR signaling via several phosphoproteins (IR, IRS1, IGF1R, PTEN, ERK, mTOR, p70S6K, RPS6) in multiple brain regions including hippocampus and entorhinal cortex. Dysregulation of Akt/mTOR phosphoproteins suggests alcohol may target this

^{*}Corresponding author: chodge@med.unc.edu.

[†]Co-first authors. J.L. Hoffman and S. Faccidomo contributed equally to this work.

pathway in AD progression. These results suggest that nondependent alcohol drinking increases the onset and magnitude of AD-like neural and behavioral pathology in 3xTg-AD mice.

1. Introduction

1.1 Overview

The impact of alcohol use on health and well-being in older adults is not fully understood. Evidence suggests that alcohol abuse during mid-life exacerbates age-related cognitive decline and may increase the risk of developing dementia after age 65. Alzheimer's disease (AD) is a major cause of dementia in older individuals but it is unclear if alcohol targets AD-linked molecular mechanisms to produce neural and behavioral pathology. This chapter is divided into two overall sections. First, we briefly review evidence suggesting that alcohol abuse promotes cognitive decline and dementia in older adults and present a re-analysis of our prior preclinical studies that assessed the impact of nondependent alcohol drinking on the neuroproteome. These data show that three primary neural mechanisms of AD (Tau, amyloid precursor protein, and presenilin-1) are the statistically most likely regulators of alcohol-sensitive protein networks in the frontal cortex and amygdala of mice, which suggests that alcohol use may promote vulnerability to AD-like pathology. Second, we present results from original preclinical studies designed to evaluate the impact of nondependent alcohol drinking on AD-like neural and behavioral pathology using the triple-transgenic mouse model of AD (3xTg-AD), which expresses human Tau, APP, and PSEN-1 transgenes. This novel work suggests that alcohol use may exacerbate the onset and magnitude of AD-like pathology in vulnerable individuals. Research that focuses on the impact of alcohol use and abuse on specific molecular mechanisms of AD will move the field forward in understanding potentially unique age-dependent vulnerability in older individuals.

1.2 Alcohol use by older adults

Human beings have consumed alcohol for millennia; its use is woven into the fabric of society and religion. In 2016 approximately 43% of the global population aged 15 years and over were current alcohol drinkers with per capita intake of 32.8g of pure alcohol per day (WHO, 2018). Although many people drink in the absence of health consequences, alcohol misuse is associated with 5.3% of all deaths and 7.2% of premature deaths worldwide (WHO, 2018). Alcohol misuse is estimated to cost the United States \$249 billion per year in health care, lost productivity, and other factors including crime and motor vehicle crashes (Sacks, Gonzales, Bouchery, Tomedi, & Brewer, 2015).

The negative impact of alcohol use on health depends on a variety of factors including age. Accordingly, the most recent strategic plan from the National Institute on Alcohol Abuse and Alcoholism (NIAAA; years 2017–2021) emphasizes the need for understanding the influence of alcohol on health and disease across the lifespan (NIAAA, 2017). Considerable research efforts have focused on the health effects of alcohol in prenatal, adolescent and young adult individuals. However, the percentage of the people aged 65 years or older who use alcohol is trending upward, has reached >40% of the population, and shows a positive correlation between age and drinking frequency (Breslow, Castle, Chen, & Graubard, 2017;

Lewis, Garcia, & Nixon, 2018). Older individuals express a variety of age-related pathologies, including neurodegenerative diseases, that increase vulnerability to other adverse health outcomes, such as poor response to and recovery from stress (Franceschi et al., 2018). Thus, alcohol use may interact with the aging process, or age-related disease conditions, to exacerbate negative health outcomes, which underscores the need for further research and public health information related to older age groups.

1.3 Alcohol, age-related cognitive decline, and dementia

Cognitive decline is a feature of normal aging that appears to be exacerbated by alcohol use and abuse. Acute alcohol intake by older individuals is associated with reduced cognitive function and blunted neural responses that mediate higher order working memory and attention as compared to younger adults (Lewis, Garcia, Boissoneault, Price, & Nixon, 2019; Squeglia, Boissoneault, Van Skike, Nixon, & Matthews, 2014). Moreover, magnetic resonance imaging studies have shown that moderate, nondependent, alcohol use (Mukamal, Longstreth, Mittleman, Crum, & Siscovick, 2001) or moderate alcohol use combined with reduced physical activity (Bittner et al., 2019) is associated with loss of gray matter in older adults, which may contribute to alcohol-induced cognitive decline. However, other evidence suggests that moderate alcohol use does not alter age-related cognitive decline (Moussa et al., 2014) suggesting that the conditions under which low to moderate levels of alcohol use may impact health and well-being in older populations are not fully understood.

Alcohol abuse and dependence are associated with a higher risk of cognitive decline and dementia. For instance, 78% of adults in their upper 70s with a history of alcohol abuse showed both cognitive impairment and increased rates of multiple forms of dementia as compared to age-matched individuals with no history of alcohol abuse (Thomas & Rockwood, 2001). In general, heavy alcohol use is associated with dementia in older populations (e.g., Mukamal et al., 2001; Truelsen, Thudium, Gronbaek, & Copenhagen City Heart Study, 2002), whereas light to moderate drinking appears to have no impact or may be protective (Ruitenberg et al., 2002).

Other data indicate that alcohol abuse in mid-life may exacerbate age-related cognitive decline and subsequent occurrence of dementia after age 65. For instance, a population-based study conducted in Australia showed that depression, bipolar disorder, anxiety, cerebrovascular disease, smoking, and alcohol dependence occurring during the mid-life decade of 55–65 years of age were all associated with significantly greater occurrence of dementia in people aged 65–69 (Zilkens, Bruce, Duke, Spilsbury, & Semmens, 2014). In that study, alcohol dependence showed an odds ratio of 4.14 (414% increase in probability) for development of dementia at age 65 that declined to 1.51 (51% increase in probability) by age 80 suggesting that the impact of alcohol on dementia risk is age-dependent both in terms of mid-life exposure and age of disease expression. Overall, evidence suggests that alcohol abuse may exacerbate age-related cognitive decline and dementia in older adults but the specific conditions under which these negative health consequences emerge and the underlying neural mechanisms remain to be fully characterized.

1.4 Alzheimer's disease

Alzheimer's disease is a progressive and irreversible neurodegenerative disorder that represents the most common cause of dementia in older populations (Alzheimer's-Association, 2016) and is the sixth leading cause of death, accounting for 93,541 fatalities in 2014—a 54% increase since 1999 (Taylor, Greenlund, McGuire, Lu, & Croft, 2017). The National Institute on Aging (NIA) estimates that over 5 million Americans have Alzheimer's disease, but this number may triple by 2050.

Alzheimer's disease is classified into three broad stages: (1) preclinical Alzheimer's disease; (2) mild cognitive impairment (MCI) due to Alzheimer's disease; and (3) dementia due to Alzheimer's disease (Albert et al., 2011; McKhann et al., 2011; Sperling et al., 2011). Clinical symptoms are absent in the preclinical stage, but brain pathology may be present. MCI of the Alzheimer's type involves memory disruption and difficulty in thinking. The progression of dementia due to Alzheimer's disease ranges from mild to moderate to severe (Albert et al., 2011; McKhann et al., 2011; Sperling et al., 2011). In the mild stage of dementia, individuals suffer from impaired memory and sensory processing but can engage in normal activities with some assistance. Moderate Alzheimer's dementia includes continued cognitive decline, impaired short- and long-term memory, loss of ability to communicate effectively and complete daily tasks. Individuals with severe dementia show worsening cognitive deficits with pronounced physical decline that includes loss of motor function and inability to eat and drink (Alzheimer's-Association, 2019). Anxiety and fear are common symptoms of neurodegenerative disorders including Alzheimer's disease (Chung & Cummings, 2000; Ferretti, McCurry, Logsdon, Gibbons, & Teri, 2001). Moreover, Alzheimer's disease patients ranging from mild to severe stages exhibit apathy (72% of patients), agitation (60%), anxiety (48%), irritability (42%), aberrant motor behavior (38%), delusions (22%), and hallucinations (10%) (Mega, Cummings, Fiorello, & Gornbein, 1996) indicating that disease progression is associated with a spectrum of neuropsychiatric abnormalities.

Prominent pathophysiological characteristics of Alzheimer's disease include plaque and neurofibrillary tangle (NFT) formation. Plaques are formed by abnormal deposits of amyloid β protein ($A\beta$) in specific brain regions (Benilova, Karran, & De Strooper, 2012; Hardy & Selkoe, 2002). $A\beta$ is derived by cleavage of amyloid precursor protein (APP) by β - or γ -secretase (e.g., PSEN-1). The long form of $A\beta$ ($A\beta_{42}$) is critical for plaque formation and is elevated in relation to the short $A\beta_{40}$ form in the brain of AD patients. Neurofibrillary tangles consist of hyperphosphorylated microtubule-associated protein Tau (pTau) (Ballatore, Lee, & Trojanowski, 2007). Numerous studies have linked the expression of plaques, tangles, and the progression of cognitive decline in Alzheimer's disease with $A\beta$ and Tau expression (Buckley et al., 2016).

1.5 Alcohol and Alzheimer's disease: Need for preclinical research

Despite an abundance of research, the etiology of Alzheimer's disease is not fully understood. Evidence suggests that 5% or fewer cases of Alzheimer's disease are “familial,” with “sporadic” classifications accounting for 95% of AD diagnoses. Thus, research is increasingly directed toward understanding the impact of the environment, lifestyles, other

disease states, and medical treatments as potential modifiable risk factors for Alzheimer's disease. A recent meta-analysis found a variety of factors related to increased risk of Alzheimer's disease including head injury in males, diabetes mellitus, use of conjugated equine estrogen with medroxyprogesterone acetate, current smoking, and low social engagement (Hersi et al., 2017).

Accordingly, a growing number of studies have evaluated alcohol use and abuse as potential risk factors for AD. Although a variety of primary studies suggest that light to moderate alcohol drinking may protect against AD in older adults (Weyerer et al., 2011), recent systematic reviews and meta analyses have concluded that there is disagreement in the field regarding the impact of alcohol consumption on AD, with divergent evidence showing that alcohol: (1) serves a protective role against AD; (2) increases AD risk; and (3) has no association with AD (Hersi et al., 2017; Piazza-Gardner, Gaffud, & Barry, 2013). One source of disagreement may derive from inconsistency in operational definitions of alcohol drinking that include imprecise groupings of patients based on light, moderate, or heavy drinking as variables. Similarly, there is variation in measures used to diagnose AD, which rely partly on inconsistent clinical evaluations ranging from telephone interviews to neurological exam. Overall, validity and consistency of alcohol use and AD diagnostic criteria represent limitations of this research and support the need for standardized clinical and research practices (Piazza-Gardner et al., 2013).

We propose, therefore, that preclinical research strategies that utilize controlled methods of alcohol exposure and evaluate standardized mechanisms of AD pathology have exceptional potential to move the field forward in understanding the impact of alcohol use on AD-like neural and behavioral pathology.

1.6 Rationale for the present study: Mechanisms of Alzheimer's disease identified as upstream regulators of alcohol-sensitive protein networks in C57BL/6J mice

As noted above, a prominent feature of AD neural pathology is the coordinate accumulation of amyloid- β (A β) protein (Hardy & Selkoe, 2002) and increased expression or phosphorylation of Tau protein (Ballatore et al., 2007), which promotes plaque and NFT formation, respectively. As part of ongoing work to discover neural mechanisms of alcohol addiction, we assessed the impact of voluntary alcohol intake on the prefrontal cortex (PFC) and amygdala (AMY) proteome in C57BL/6J mice (Agoglia & Hodge, 2017; Salling et al., 2016). These brain regions were chosen for analysis based on known involvement in the rewarding, or reinforcing, effects of alcohol (Agoglia, Holstein, Reid, & Hodge, 2015; Agoglia, Sharko, et al., 2015; Besheer, Cox, & Hodge, 2003; Faccidomo, Reid, Agoglia, Ademola, & Hodge, 2016; Faccidomo, Salling, Galunas, & Hodge, 2015; Hodge, Chappelle, & Samson, 1996; Olive & Hodge, 2000; Salling et al., 2017; Schroeder, Olive, Koenig, & Hodge, 2003; Schroeder et al., 2008; Ueno et al., 2001). In each study, nondependent mice consumed alcohol (10%, v/v) vs water or water only in the home-cage for ~1 month (Fig. 1A). Changes in the AMY or PFC neuroproteome were assessed 24-h post alcohol via two-dimensional differential in-gel electrophoresis (2D-DIGE) with protein identification by MALDI/TOF/TOF mass spectrometry (Fig. 1B). Alcohol intake (~12g/kg/day) consistently (n = 4 replicate gels per brain region) altered an array of fundamental protein networks that

regulate a range of diseases, biological functions, molecular and cellular functions, and developmental processes suggesting that alcohol may impact health and vulnerability to disease across the lifespan (Agoglia & Hodge, 2017; Salling et al., 2016).

Here, we reanalyzed fold-change data (alcohol intake vs control) from the alcohol-sensitive protein networks (Agoglia & Hodge, 2017; Salling et al., 2016) using Ingenuity Pathway Analysis (IPA) Upstream Regulator Analysis (URA) to elucidate potential upstream regulatory molecules that may explain observed changes in protein networks (Kramer, Green, Pollard, & Tugendreich, 2014). In the PFC and AMY datasets, the URA identified MAPT (Tau), APP (amyloid precursor protein), and PSEN-1 (presenilin-1) as the most probable upstream modulators of alcohol-sensitive protein networks (Fig. 1C). In the PFC, 12 Alzheimer's-associated proteins were identified as downstream targets of Tau, APP, and PSEN-1 (Fig. 1D, left). Similarly, 11 Alzheimer's-associated proteins were identified in the AMY as downstream targets of Tau, APP, and PSEN-1 (Fig. 1D, right). These findings indicate that alcohol intake influences protein networks that are downstream of primary molecular determinants of AD, which suggests that alcohol may influence risk of AD-related pathology in the PFC and AMY.

In addition to their importance in Alzheimer's disease, these proteins regulate critical molecular and cellular functions in the brain. IPA Core Analysis showed that the alcohol-sensitive protein clusters play important roles in energy metabolism and homeostasis (ATP5D, HK1, AK1, PGAM1, CKB), cytoskeletal development and function (BASP1, CAP1, DPYSL2 [CRMP2], ALDOA, TUBA1A, CFL2, ACTG1), cell signaling and endocytosis (STXB1[MUNC-18], ALDOA, AMPH, CPLX2, CLTA), cellular/oxidative stress (HSPA5, HSPA8, ENO1, ENO2), transcription and DNA regulation (PURA, YWHAZ). While we did not find direct overlap between the significantly changed proteins in the mPFC and AMY, similar protein families emerged, including the heat shock proteins, proteins involved in the SNARE complex, and enolase proteins suggested related mechanisms of action between brain regions.

Predictably, many of the alcohol-sensitive proteins are abnormally expressed in the brains of AD patients. Indeed, proteomic studies of CSF/plasma from human Alzheimer's patients (Robinson, Amin, & Guest, 2017) and transgenic mouse models of AD (Chang, Nouwens, Dodd, & Etheridge, 2013; Fu et al., 2015; Takano et al., 2013) show considerable overlap between AD-linked protein networks and the alcohol-sensitive networks shown here. Notably, heat shock proteins and creatinine kinases were upregulated and total levels of DPYSL2 (CRMP2) a microtubule protein, was decreased in the proteomics study but is consistently hyperphosphorylated in postmortem human brains and transgenic lines. This is a consistent, yet curious, finding because heat shock proteins are thought to protect the brain from increasing amounts of oxidative stress and toxicity due to accumulated A β aggregates (Rivera, Capone, Cauvi, Arispe, & De Maio, 2018). It is possible that HSPs are increasing in a compensatory fashion in response to both the detrimental consequences of alcohol and of increasing levels of AB in the brain. Likewise, total levels of CRMP2 may be blunted in the alcohol-drinking mice because more of the protein may be phosphorylated and starting to aggregate with Tau and AB proteins. Both heat shock and CRMP proteins appear to react

quickly to stress and chronic alcohol drinking and given their link to AD pathology, they may be useful early biomarkers for AD-like pathology associated with alcohol use or abuse.

Further preclinical research is needed to elucidate the impact of alcohol drinking on MAPT, PSEN-1 and APP to determine if alcohol targets these systems to increase risk of developing neural and behavioral pathologies associated with AD.

1.7 Translational approach: Selection of the triple-transgenic mouse model of AD

Although no animal model recapitulates all aspects of AD, existing transgenic mouse lines are available that express specific aspects of the disease including amyloid plaques, NFTs, neurodegeneration and behavioral deficits that are consistent with human pathology. Examples of mouse models of AD that express human APP, PSEN-1 and Tau transgenes are listed in Table 1 (see Jankowsky & Zheng, 2017; Webster, Bachstetter, Nelson, Schmitt, & Van Eldik, 2014 for more comprehensive reviews). These and other transgenic mouse lines can be used in combination with alcohol exposure methods (e.g., voluntary drinking, dependence induction, withdrawal, etc.) in preclinical studies to model the impact of alcohol use or misuse on brain and behavioral functions in AD-vulnerable individuals. This relatively unexplored strategy could move the field forward in understanding the impact of alcohol use on health and well-being in older individuals.

Transgenic models that express APP or PSEN-1 mutations may be utilized for identifying alcohol-mediated changes in brain and behavioral function linked specifically to amyloid pathology. As discussed above, APP is cleaved by γ -secretase (e.g., PSEN-1) to form A β peptides (A β 40 and A β 42), which contribute to amyloid plaques in AD. Transgenic mouse lines that express APP or PS1 mutations, or their combination, exhibit amyloid pathology such as elevated A β 42/A β 40 ratio and presence of plaques. A recent study showed that APP23/PS45 mice that express a double (APP/PSEN1) transgenic mutation exhibit increased APP, β -secretase 1, A β 40, and A β 42 following alcohol binge-like exposure with concomitant deficits in spatial learning and memory (Huang et al., 2018). The widely used 5XFAD mouse line express a total of five human APP and PSEN-1 trans-genes, which results in rapid onset of amyloid plaques throughout the cortex and hippocampus as early as 2 months of age (Oakley et al., 2006) and could, therefore, be used to assess site-specific amyloid pathology associated with alcohol exposure. The 5XFAD mouse line also shows a deficit in spatial memory (Xiao et al., 2015) suggesting that cognitive decline associated with amyloid pathology can be modeled in APP/PSEN-1 transgenic mouse lines.

Neurofibrillary tangles are a prominent feature of AD pathology that are formed by aggregates of hyperphosphorylated Tau protein. Transgenic mouse lines that express human Tau mutations develop tangles and show deficits in mouse behavioral tests that model cognitive decline in AD. Evidence suggests that the majority of hippocampal- and entorhinal-based cognitive deficits (>80%) in AD patients is correlated with NFTs (Giannakopoulos et al., 2003); thus, evaluating Tau-dependent neural and behavioral deficits has strong translational value. As noted above (Fig. 2), NFT pathology is expressed in AD in a brain region-dependent manner originating in the entorhinal cortex and progressing to the hippocampus, other areas of the cortex, and limbic structures. Mouse lines that express mutations of human Tau (e.g., 3xTg-AD mice) also show this anatomical progression of

pathology and are, therefore, useful for evaluating the impact of alcohol and other potential modifiable risk factors on the development of AD-like pathology.

Based on results of the URA that identified MAPT, APP, and PSEN-1 as regulators of alcohol's impact on the neuroproteome, the present set of studies were designed to utilize the “humanized” triple-transgenic mouse model of AD (3xTg-AD mice). This mouse model carries a knock-in mutation of three human genes detected in our analysis: presenilin (PSEN-1_{M146V}), amyloid beta precursor protein (APP_{Swe}), and microtubule-associated protein Tau (TauP30IL), expressed on a hybrid C7BL/6;129X1/SvJ;129S1/Sv genetic background (Oddo, Caccamo, Shepherd, et al., 2003). The 3xTg-AD mouse line is a well-validated animal model of AD that develops rapid age-dependent and progressive AD-like neuropathology including A β deposits and elevated Tau (Billings, Oddo, Green, McGaugh, & LaFerla, 2005; Oddo, Caccamo, Kitazawa, Tseng, & LaFerla, 2003; Oddo et al., 2006). These neuropathies are associated with behavioral deficits including cognitive decline and altered emotional processing that are characteristic of AD (Filali et al., 2012; Pietropaolo, Feldon, & Yee, 2014; Romano et al., 2014; Webster et al., 2014). A meta-analysis of 51 studies using the 3xTg-AD mice found that Tau and A β (40 and 42) expression showed a strong association with impaired cognitive function (Huber, Yee, May, Dhanala, & Mitchell, 2018).

Importantly, it is highly significant that 3xTg-AD mice express Tau, APP, and PSEN-1, which our neuroproteomic studies have shown are the main modulators of alcohol-sensitive protein networks within the AMY (Salling et al., 2016) and PFC of mice (Fig. 1). To our knowledge, this innovative transgenic model of AD vulnerability has not been studied in the alcohol field leaving untapped potential for discovering alcohol-induced changes in pathology.

1.8 Translational approach: Analysis of standardized biomarkers of AD-like pathology in 3xTg-AD mouse brain

As noted above, one source of disagreement in research efforts to evaluate alcohol use as a potential risk factor for AD is the lack of standardized diagnostic and research criteria (Piazza-Gardner et al., 2013). Alzheimer's disease was originally defined as a clinical syndrome with postmortem neuropathologic verification. In 2018, the NIA and the Alzheimer's Association (AA) jointly developed the NIA-AA Research Framework for understanding AD as an aggregate neuropathology defined by specific biomarkers in combination with postmortem examination (Jack et al., 2018). Adhering to an AT(N) rubric, it was recommended that AD research should evaluate: A β pathology (A); Tau pathology (T); and neurodegeneration (N) with specific biomarker combinations indicating disease state (Table 2).

In humans, these biomarkers can only be evaluated in plasma and CSF during life making it difficult to evaluate the influence of alcohol use on AD-related brain pathology during early disease stages. Alternatively, the present preclinical studies utilized the 3xTg-AD mouse model, to evaluate A β and Tau pathology in specific brain regions as a translational approach to understand the impact of alcohol drinking on disease progression. By focusing on the NIA-AA Research Framework, the present study has potential to: (a) complement

NIA efforts to understand causes of AD; and (b) expand knowledge of alcohol-induced neuropathology in support of NIAAA efforts to understand the impact of alcohol across the lifespan.

1.9 Overall hypothesis: Alcohol use impacts Alzheimer's disease progression

The progression of Alzheimer's disease is divided into stages based on the severity of behavioral and neural pathology (Braak & Braak, 1998; Palmer, 2002). AD-related neuropathies result in cell damage and death in a brain-regional progression moving from the entorhinal cortex to the hippocampus (HPC) and frontal cortex, and finally to limbic systems, including the AMY with corresponding escalation of behavioral pathology (Pietrzak et al., 2015; Sperling et al., 2011; Villemagne et al., 2013) (Fig. 2A). Cognitive decline is initially associated with A β and Tau pathology in the entorhinal cortex (*mild*). With disease progression, pathology spreads to the HPC and neocortex (*moderate*) and symptoms include more prominent memory loss. Finally, in the latter stages of AD, pathology progresses to the AMY and striatum (*severe*) with increasing pathology and severity of symptoms (Palmer et al., 2011) (Fig. 2A).

The impact of alcohol use on A β and Tau pathology in specific brain regions and association with and cognitive function is not fully understood. To address this gap in knowledge, we conducted a set of translational studies in 3xTg-AD mice designed to test the overall hypothesis that voluntary alcohol drinking exacerbates the onset and magnitude of AD-related neural and behavioral pathology (Fig. 2B). These studies can provide significant public health information for approximately 80% of adults who have consumed alcohol in a nondependent manner. Moreover, understanding the impact of alcohol drinking on AD pathology has potential to lead to novel diagnostic, prevention, and treatment options for this large segment of the population.

2. Materials and methods

2.1 Mice

Male (n = 7) and female (n = 3) 3xTg-AD (B6;129-Tg(APP^{Swe},TauP301L) 1Lfa *PSEN-1^{tm1Mpm}*/Mmjax) triple-transgenic homozygous mice were used in these studies. The 3xTg-AD mouse line was generated by Dr. Frank LaFerla at UC Irvine (Oddo, Caccamo, Shepherd, et al., 2003) and provided for use in these studies via the Mutant Mouse Resource & Research Center Repository (MMRRC stock #34830) at Jackson Labs (Bar Harbor, ME) under an approved Material Transfer Agreement with UC Irvine. Background strain- and sex-matched B6129SF2/J mice (male [n = 7] and female [n = 3]) were used as wild-type (WT) controls where appropriate. Data from male and female mice were combined but due to low sample size, methods were underpowered to detect sex differences.

The 3xTg-AD mice are a well-validated "humanized" animal model that uniquely expresses plaques, tangles, and associated cellular and brain-regional pathologies associated with Alzheimer's disease (Oddo, Caccamo, Shepherd, et al., 2003). The 3xTg-AD mice were derived single-cell embryos from mice bearing a knock-in mutation of human presenilin (PS1^{M146V}) on a mixed C7BL/6;129X1/SvJ;129S1/Sv genetic background (B6;129-

PSEN-1^{tm1Mpm}). These mice were co-injected with two mutant human transgenes for amyloid beta precursor protein (APP_{Swe}) and microtubule-associated protein Tau (Tau_{P30IL}). Both transgenes integrated at the same locus.

All mice were at 8 weeks of age upon arrival from Jackson Labs. Mice were group-housed (n = 4/cage) in tecniplast cages (12" × 6.5" × 7") until 2 weeks prior to the initiation of self-administration procedures. At all times, mice had with ad libitum access to food (Purina Isopro 3000) and water, the temperature of the vivarium was maintained at 21 ± 1 °C, humidity was maintained at 40 ± 2%, and the lights were on a reverse 12L:12D cycle (lights on at 0800). All experiments were approved by the Institutional Care and Use Committee at the University of North Carolina-Chapel Hill and were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals (NIH Publication 80–23).

2.2 Two-bottle home-cage alcohol or saccharin intake

Mice were singly housed for 2 weeks prior to initiation of home-cage alcohol drinking studies. Voluntary alcohol drinking studies were conducted as previously reported in Hodge et al. (1999); Ueno et al. (2001); Besheer, Lepoutre, Mole, and Hodge (2006); Stevenson et al. (2009); Holstein, Spanos, and Hodge (2011); Agoglia, Holstein, et al. (2015); Agoglia, Holstein, Eastman, and Hodge (2016); Salling et al. (2016); and Faccidomo et al. (2018). Briefly, mice were given continuous 24h access to two 50mL bottles containing sweetened alcohol (25%, w/v + saccharin 0.1%, w/v) or water for 4 months (120 days). Parallel control groups had continuous access to 2 bottle containing saccharin (0.1% w/v) or water. Fluid consumed was measured every 48h and the position of the bottles (left or right) was alternated to avoid a side preference. Food was available ad libitum. Dependent measures included volume of fluid consumed, alcohol dose (g/kg/day) and alcohol and saccharin preference. Two-bottle choice drinking ended 24h prior to the first behavioral test day (open field activity). During all behavioral testing, which occurred during 1–3 weeks post alcohol, mice had ad libitum access to water only (Fig. 3). Behavioral testing occurred in the following sequence with a minimum of 1 day in between each test: open field locomotion, rotarod, Morris Water Maze, prepulse inhibition, fear conditioning.

2.3 Open field locomotion

Spontaneous locomotor activity and habituation to a novel environment was measured in a computer controlled open field chamber (41cm × 41cm × 30cm; Versa Max, AccuScan Instruments). Locomotor distance traveled (cm) was measured by three sets of infra-red photobeams placed on opposite walls to record x–y ambulatory movements during a single session.

2.4 Rotarod

Rotarod was used to assess graded motor coordination and balance in mice over 3 repeated trials. Each trial was a maximum of a 5-min test and there was a brief inter-trial interval (45s). Mice were placed on a rotating barrel (3cm) of a rotarod apparatus (Ugo-Basile, Stoelting Co., Wood Dale, IL) which progressively accelerated from 3rpm to 30rpm. The latency to fall off or rotate around the top of the barrel was recorded as the primary measure of neuromuscular coordination.

2.5 Morris Water Maze

This test was used to assess acquisition and memory of spatial learning. The apparatus was a large, circular pool (diameter = 122cm; 45cm deep), filled with water (24–26°C) and surrounded by four discrete extra-maze cues effectively dividing the apparatus into quadrants. The water was made opaque with nontoxic poster paint. A camera suspended above the maze was connected to Noldus Ethovision (Ethovision, Noldus Information Technology, Wageningen, the Netherlands). Dependent measures included swimming distance, velocity, latency to find the platform, time spent in each quadrant, path efficiency to the platform.

For *habituation and assessment of visual ability*, mice were given four trials in a visual platform stage. During this stage, extra-maze cues were removed and the platform (12cm in diameter) was made visible above the water surface with a flag attached to the platform. Mice were randomly placed into the pool in one of four possible locations and were given up to 60s per trial to find the platform. If a mouse failed to locate the platform in 60s, it was placed on the platform for 10s before being removed and allowed to rest (30-s inter-trial interval) before starting the next trial.

For *acquisition of spatial learning*, mice were tested for the ability to find a submerged escape platform with the use of spatial cues. During this stage, extra-maze cues were evenly placed around the pool to divide it into quadrants. Mice were given four trials daily until they reached criterion for learning (<15s to find the platform). If a mouse failed to locate the platform in 60s, it was placed on the platform for 10s before being removed and allowed to rest (30s inter-trial interval) before starting the next trial. Spatial learning was demonstrated by a decrease in the latency to find the escape platform and increased efficiency in the path taken to reach the platform.

For *assessment of spatial memory*, a probe trial was conducted 1h after the final acquisition trial. During the probe trial, mice were placed in the pool for 60s in the absence of the platform but with extra-maze cues in place. Time in each quadrant of the pool and the number of crossings of the target location (where the platform was located during training) was assessed and used to demonstrate memory of the platform location. Spatial memory was demonstrated by a preference for the quadrant where the platform had been located, in comparison to other quadrants of the pool.

2.6 Fear conditioning

This standard test was used to assess emotional processing and learning and memory. Cued fear conditioning was conducted over 3 days using an image tracking system (MED Associates, St. Albans, VT). On day 1, mice were given a 7-min training session in which they were placed in the test chamber contained in a sound attenuating box and allowed to explore for 2min. Mice were then exposed to a 30-s tone (80dB), followed by a 2s foot shock (0.4mA). Mice received an additional two shock-tone pairings during the training session. On day 2, mice were placed back into the test chamber and freezing behavior (immobility) was recorded as a measure of context-dependent learning across a 5-min session. On day 3, mice were evaluated for associative learning to the auditory cue across a

5-min session. Prior to the session, the chamber was modified to conceal contextual cues by using an acrylic insert to change wall and floor surfaces; additionally, a mild novel odor (dilute vanilla flavoring) was added to the sound attenuating box. Mice were then placed into the modified chamber and allowed to explore for 2min, then the acoustic stimulus was presented for the remaining 3min of the session. Freezing behavior before and during the stimulus were recorded.

2.7 Acoustic startle and prepulse inhibition

Prepulse inhibition was assessed as a classic measure of reflexive whole-body information processing and movement (startle response), and sensory motor gating that occurs in response to a sudden, unexpected noise. Prepulse inhibition occurs when a softer sound (the prepulse) precedes a louder sound (acoustic startle) leading to a blunted startle response in the individual.

To test this behavior in the mouse, they were placed in a small acrylic cylinder that was seated upon a piezoelectric transducer and located inside a larger sound attenuating chamber (San Diego Instruments SR Lab system). Each chamber contained a ceiling light, fan, and a loudspeaker for the acoustic stimuli (bursts of white noise) and was connected to a computer running SR Lab software which quantifies movement and vibrations during each trial. The test session consisted of 42 trials, presented following a 5-min habituation period, with 7 different types of trials: no-stimulus trials, trials with the acoustic startle stimulus (40ms; 120dB) alone, and trials in which a prepulse stimulus starting 4dB above background (20ms; 74, 78, 82, 86, 90dB) had onset 100ms before the onset of the startle stimulus. The different trial types were presented in blocks of 7, in randomized order within each block, with an average inter-trial interval of 15s (range: 10–20s). Measures were taken of the startle amplitude for each trial, defined as the peak response during a 65-ms sampling window that begins with the onset of the startle stimulus. Levels of percent prepulse inhibition were calculated as $100 - (\text{prepulse response} / \text{startle response}) \times 100$.

2.8 Measuring NIA-AA biomarkers in brain

2.8.1 Multiplex array-based immunoassay of A β and Tau—Luminex® flow cytometry-based technology allows for simultaneous quantification of proteins in a single multiplex assay, thus providing an advantage of increased throughput and decreased volume needed per sample. This is achieved via fluorescent-coded magnetic polystyrene microspheres (80;6.45 μ m) which are coated with specific capture antibodies that allow multiple proteins to be measured via sandwich ELISAs in a single sample. Using the Luminex® 200 platform, our lab used the MILLIPLEX® MAP Human Amyloid Beta and Tau Panel (Kit # HNABTMAG-68K) to quantify A β 40, A β 42, Total Tau proteins (Tau), and Phosphorylated Tau Thr181 (pTau) following manufacturer protocol (Luminex® Corp, Austin TX; EMD Millipore Corporation, Billerica, MA).

Ten days after the final behavioral test (1-month post alcohol or saccharin intake; Fig. 3), mice (N = 11) were rapidly decapitated, and brains were quickly removed and flash-frozen in cold isopentane (−40°C; 2-methylbutane; Sigma-Aldrich) for use with the multiplex assays described below. Thick coronal sections (0.8–1.0mm) were taken on a cryostat (Leica

Biosystems), and using a mouse brain atlas (Franklin & Paxinos, 2001), circular tissue punches (1mm diameter) were collected from the prefrontal cortex (PFC), medial prefrontal cortex (mPFC), nucleus accumbens (Acb), amygdala (AMY), medial hippocampus (mHPC), lateral hippocampus (LHPC), CA1 region of the hippocampus (CA1), lateral entorhinal cortex (LEC) and medial entorhinal cortex (MEC). Tissue punches from each brain region were homogenized with an ultrasonifier in 100µL of buffer (pH7.4) containing 20mmol/L Tris-HCl, 7.8mmol/L Tris-Base, 150mmol/L NaCl, 0.02% Tween-20, and a cocktail of phosphatase and protease inhibitors (HALT) and frozen at -80°C until analysis.

Samples and reagents were thawed to room temperature and used according to manufacture protocol. Samples were diluted to 1:2 with assay buffer included in kit. Briefly, a provided lyophilized standard was reconstituted, diluted in serial fashion to create standard curves for each of the kit analytes. The standards provided quality control samples (reconstituted) and experiment samples were then added to a flat bottom 96 well plate included in the kit. Biotinylated detection antibodies were added, followed by the addition of the mixed magnetic beads. The plate was then sealed for overnight incubation at room temperature on orbital shaker (700rpm) protected from light. The next day, the plate was washed using a handheld magnet (EMD Millipore Catalog #40-285) to retain the magnetic beads during decanting. Next, Streptavidin-PE conjugate, a reporter molecule, was added to each well and incubated on a shaker at room temperature for 30min to allow each bead to be individually identified and quantified based on fluorescent signals. After an additional round of plate washing, a final volume of wash buffer was added to the plate in place of sheath fluid for the plate to be read and discourage aggregation during the assay. The plate was read using the Luminex® 200 system equipped with xPONENT® 3.1 software. The standard curve and analyte concentrations were calculated using Milliplex Analyst 5.1 software (EMD Millipore Corporation, Billerica, MA, USA). Dilution control procedures identified a prozone effect for total Tau, which is common in Luminex and other ELISA based assays in the presence of high antigen levels (Jacobs, van der Molen, Bossuyt, & Damoiseaux, 2015), and prevented cross-plate standardization. Thus, Median Fluorescence Intensity (MFI) was measured for Tau within a single plate for each brain region analyzed.

2.8.2 pTau immunohistochemistry (IHC)—In order to qualitatively assess levels of pTau expression in 3xTg-AD mice 1month post alcohol or saccharin intake (Fig. 3), a subset of mice (N = 2) were deeply anesthetized with 100mg/kg pentobarbital and were intracardially perfused with freshly prepared, ice cold, phosphate buffered saline (1M PBS, pH 7.4), followed by 4% paraformaldehyde (PFA). Whole brains were extracted, post-fixed in 4% PFA for 48h, and then stored in PBS at 4°C. Coronal brain sections were sliced using a vibratome (Leica VT1000S) and stored in cryoprotectant (recipe) at -20°C until IHC was conducted. A subset of coronal brain sections from the anterior HPC and AMY of WT and 3xTg-AD mice with a history of saccharin or alcohol drinking were processed for fluorescent immunohistochemistry as previously published (Besheer & Hodge, 2005; Salling et al., 2016; Stevenson et al., 2009). Briefly, sections were incubated in methanol to facilitate cell permeabilization, in hydrogen peroxide to block endogenous peroxidase activity and in a blocking buffer of Normal Goat Serum (Vector Labs) +0.1% Triton-X in PBS (PBSTx) to inhibit non-specific binding. Next, sections were incubated overnight at RT with an anti-

rabbit phosphor-Tau-Ser^{199,202} polyclonal primary antibody (1:500; Invitrogen, #44–768G). The following day, sections were washed and incubated at RT with an Alexa Fluor® 488 AffiniPure Goat Anti-Rabbit IgG (1:200) secondary antibody prior to slide mounting. Fluorescence was visualized with an Olympus BX51 microscope.

2.9 Multiplex assay for the Akt/mTOR signaling pathway

To maximize efficiency and data output from our limited sample, a multiplex cell signaling assay was run on the Luminex® platform as an alternative to Western blotting. The MILLIPLEX® MAP Akt/mTOR Phosphoprotein 11-plex Magnetic Bead Kit (#48–611MAG) was used in conjunction with MILLIPLEX® MAP Phospho ERK/MAPK 1/2 (Thr185/Tyr187) Magnetic Bead MAPmate™ and MILLIPLEX® MAP Total β -Tubulin Magnetic Bead MAPmate to simultaneously detect 12 phosphoproteins [phosphorylated p70S6K (Thr412), IRS1 (Ser636), GSK3 α (Ser21), GSK3 β (Ser9), Akt (Ser473), PTEN (Ser380), IR (Tyr1162/Tyr1163), IGF1R (Tyr1135/Tyr1136), RPS6 (Ser235/Ser236), TSC2 (Ser939), and mTOR (Ser2448), ERK/MAPK 1/2 (Thr185/Tyr187)] with β -tubulin serving as a loading control. The assay was conducted following manufacturer protocol (EMD Millipore Corporation, Billerica, MA, USA).

Briefly, samples were diluted to the approximately 10 μ g of total protein (working range for assay was 1–25 μ g) using provided assay buffer. Additional analyte beads (ERK and β -tubulin) were added to the 11 premixed magnetic beads and added to each well in a 96 well plate. Samples and reconstituted control cell lysates (stimulated and unstimulated) were added to the plate and incubated with bead mixture overnight (16–20h) at 2–8°C on a plate shaker (700rpm) protected from light. The plate was washed using a handheld magnet (EMD Millipore Catalog #40–285) to retain the magnetic beads during decanting. Biotinylated detection antibodies were added to the plate and incubated on a shaker at room temperature, protected from light for 1h. Detection antibody was decanted and Streptavidin-Phycoerythrin (SAPE) was added and incubated on a shaker at room temperature, protected from light for 15min. Next, a provided amplification buffer was added and allowed to incubate on a shaker at room temperature, protected from light for 15min. Finally, this solution was decanted, and the beads were suspended in assay buffer before being read using the Luminex® 200 system equipped with xPONENT® 3.1 software. Median fluorescence intensity was normalized against EGF stimulated control lysate and then relative quantification was calculated against the loading control.

2.10 Drugs

Alcohol solutions (25%, w/v) were prepared by diluting 95% EtOH (Pharmco Products Inc., Brookfield, CT) with a saccharin (0.1%, w/v) solution. Saccharin (0.1%, w/v; Millipore Sigma, St. Louis, MO) was prepared in water. Pentobarbital (60mg/mL) was dissolved in ddH₂O and administered via intraperitoneal injection with a 27G needle.

2.11 General data analyses

Data are presented graphically and analyzed statistically using GraphPad Prism (GraphPad Prism, Chicago, IL, USA). Data were analyzed statistically by analysis of variance (ANOVA) followed by post hoc multiple comparisons where appropriate.

2.12 Bioinformatics

The IPA Upstream Regulator analysis was conducted to identify potential mechanisms of alcohol-induced changes in the neuroproteome. This analysis identifies a cascade of upstream regulators that can explain the observed changes in protein expression. Identification of statistically most likely regulators is based on expected effects between potential regulators and their target proteins stored in the Ingenuity® Knowledge Base. The analysis examines how many known targets of each regulator are present in the dataset and compares direction of change in experimental data to what is expected from the literature in order to predict likely regulators. Overlap *P* values represent the probability of upstream regulators based on significant overlap between dataset proteins and known targets of potential regulator proteins.

3. Results and discussion

3.1 Alcohol and saccharin intake

To explore the potential long-term impact of nondependent alcohol drinking on specific AD biomarkers, four groups of age-matched (3 months) 3xTg-AD and WT control mice (combined male [*n* = 14] and female [*n* = 6]; *N* = 20 in total) were given a choice between: (1) alcohol [(25%, w/v) + saccharin (0.1%, w/v) vs water (*n* = 6)]; or (2) saccharin [(0.1%, w/v) vs water (*n* = 4)] for 11 weeks according to our standard two-bottle choice 24-h home-cage procedure (Methods; Fig. 4A and B). There were no statistically significant differences in total alcohol or saccharin intake between 3xTg-AD and WT mice (male and female data combined). Average total alcohol intake ranged from 13.7 to 17.8g/kg/day with preference ratios (alcohol/total fluid) ranging from 36% to 39% between genotypes (Fig. 4A). This level of alcohol intake is below the threshold for induction of physical dependence (e.g., Ogata, Ogato, Mendelson, & Mello, 1972) and observation of mice in this study detected no signs of dependence or withdrawal.

Saccharin intake ranged between 3.5 and 4.8mL/day with preference ratios between 77% and 81% between genotypes (Fig. 4B). However, when drinking data were plotted in weekly averages (Fig. 4A and B), there was a significant interaction of genotype and time ($F(10,100) = 2.299$). Post-hoc tests revealed that this interaction was driven by a significant difference in alcohol intake between the WT and 3xTg mice during the first week of self-administration, with 3x-Tg mice consuming more alcohol than their wild-type counterparts. This difference was not significantly different by week 2 and by week 7, both groups consumed similar amounts of alcohol. No differences were observed in body weight between genotypes or treatment groups (Fig. 4C). Next, during a 3-week alcohol-free period, 7-month-old mice were tested on a battery of behavioral tests in randomized order.

3.2 Normal motor function

Mouse models of AD show behavioral deficits on a variety of tasks that model aspects of the human disease including passive avoidance, fear conditioning, and various mazes (Webster et al., 2014). Since these and other commonly used tasks require motor function, interpretation of altered performance can be complicated by the presence of motor deficits. Evidence indicates that 3xTg-AD show reduced locomotor activity in the open field at 12–

18 months of age (Filali et al., 2012; Gulinello et al., 2009). By contrast, 3xTg-AD mice at both 6 months (Stover, Campbell, Van Winssen, & Brown, 2015b) and 16 months (Garvock-de Montbrun, Fertan, Stover, & Brown, 2019) of age show improved performance as compared to WT controls on the rotarod test suggesting improved motor coordination. Importantly, however, 16-month-old 3xTg-AD mice show an age-dependent deficit in performance on rotarod, grip strength, gait analysis and balance beam tests as compared to younger 6-month-old 3xTg-AD mice (Garvock-de Montbrun et al., 2019). Overall, these findings underscore the importance of evaluating performance of 3xTg-AD mice on AD-related cognitive tasks in the context of potential motor abnormalities.

As noted above, behavioral testing in the present study was conducted in 3xTg-AD mice and WT controls at 7 months of age. To determine if alcohol intake altered motor function in this age range, we evaluated 3xTg-AD and WT mice in the open field and rotarod tests during the first week after alcohol exposure. In the open field test, 3xTg-AD mice showed levels of spontaneous locomotor activity and habituation that were not different than WT mice (Fig. 4D). There was also no effect of genotype or history of alcohol intake. Three-way repeated measure (RM)-ANOVA (genotype $\times$ alcohol $\times$ time) found a significant main effect of time [$F(2.040, 32.64) = 34.84, P < 0.0001$] with no main effect of genotype or alcohol intake, and no interactions among the variables. This indicates that mice from all groups showed similar levels of activity and habituation to the environment, which suggests the absence of deficits in gross motor function or habituation learning. When tested on the rotarod, performance of all mice improved as a function of repeated trials (Fig. 4E). Three-way ANOVA showed a significant effect of trial [$F(1.825, 29.19) = 37.74, P < 0.0001$], but there was no effect of alcohol intake or genotype, and no interaction among the variables. These data indicate that there are no abnormalities in motor ability among the genotypes or alcohol intake conditions at this age.

3.3 Alcohol-induced deficit in spatial memory in 3xTg-AD mice

To assess cognitive function, alcohol and saccharin exposed 3xTg-AD and WT mice were tested in the Morris Water Maze (MWM), which is a hippocampal-dependent measure of place navigation (Morris, Garrud, Rawlins, & O'Keefe, 1982). The MWM is widely used as a preclinical measurement of reference memory and working memory (Webster et al., 2014). At the conceptual level, the MWM task recapitulates symptoms seen in human AD patients including confusion and getting lost due to difficulty with navigation. Numerous mouse genetic models of AD have been tested in the MWM and most show diminished performance that is consistent with AD-like cognitive deficits (e.g., Lalonde, Dumont, Staufenbiel, & Strazielle, 2005; Ohno et al., 2007; Webster et al., 2014).

3.3.1 Spatial learning—Results showed that 3xTg-AD mice exhibited a deficit in acquisition of spatial learning that was not altered by alcohol exposure (Fig. 5A, left), which is consistent with known performance of this mouse strain (Huber et al., 2018). Three-way RM-ANOVA (genotype alcohol trial) identified a significant main effect of trial [$F(2.006, 24.07) = 3.511, P = 0.0458$] and genotype [$F(1, 12) = 7.841, P = 0.02$]. However, there was no main effect of alcohol exposure or an interaction among the variables.

These data show that 3xTg-AD mice at 7 months of age exhibit a deficit in spatial learning as demonstrated by increased escape latencies during the acquisition phase of the MWM test irrespective of treatment condition. This result is consistent with prior evidence showing that at 6 months of age, 3xTg-AD mice require more trials to reach criterion (escape latency) when learning the MWM task, which was demonstrated by single-trial analysis to be a function of impaired memory function during the multi-day procedure (Billings et al., 2005).

Importantly, there is no evidence in the present study that a history of alcohol intake altered spatial learning by 3xTg-AD mice or WT controls. However, since neural (Oddo, Caccamo, Shepherd, et al., 2003) and behavioral (Garvock-de Montbrun et al., 2019) pathology continues to develop in 3xTg-AD mice after 12 months of age, it will be important for future studies to evaluate the impact of alcohol use on spatial learning in older mice.

3.3.2 Spatial memory probe trial—When tested 1h after the last learning trial, alcohol-exposed 3xTg-AD mice exhibited a significant memory deficit as shown by less time spent in the quadrant previously containing the escape platform (Fig. 5A, right), which is consistent with an alcohol-induced deficit in hippocampal-dependent spatial memory. Two-way ANOVA (genotype alcohol exposure) found no main effect of genotype or alcohol but identified a significant interaction between those factors [$F(1, 13) = 5.018, P = 0.0432$], indicating that the effects of alcohol depend on genotype. Multiple comparison procedures showed that alcohol-exposed 3xTg-AD mice spent significantly less time in the quadrant that previously contained the escape platform (Fig. 5A, right).

Prior research has shown that 3xTg-AD exhibit impaired spatial memory on short-term (1.5-h) and long-term (24-h post training) memory probe trials in the MWM (Billings et al., 2005). Our results differ from that work, however, in that only the alcohol-exposed 3xTg-AD mice demonstrated a memory deficit on the probe trial conducted 1-h post acquisition (Fig. 5A). This deficit in performance on the probe trial could be a function of poor performance during acquisition; however, this interpretation does not seem likely since saccharin exposed (control) 3xTg-AD mice showed a similar pattern of performance during acquisition but exhibited normal performance on the memory probe trial. This suggests that the level of performance by both groups of 3xTg-AD mice during acquisition was sufficient to support normal performance on the probe trial. Overall, these data indicate that nondependent alcohol use produced a deficit in hippocampal-dependent spatial memory.

Since deficits in spatial navigation are pronounced in AD, this finding is important from a translational perspective. The HPC is an initial locus of neurodegeneration in patients affected by Alzheimer's disease (Braak & Braak, 1991; Whitwell, 2010) with diminished navigational ability presenting as one of the first clinical symptoms (Cherrier, Mendez, & Perryman, 2001; Pai & Jacobs, 2004). Evidence indicates that AD targets specific navigational skills in humans including route learning (e.g., specific orienting skills) and topographic memory or memory for landmarks (e.g., spatial memory and perception) (Lithfous, Dufour, & Despres, 2013). Thus, the present finding that 3xTg-AD mice show diminished spatial learning irrespective of alcohol exposure is consistent with initial development of AD-like pathology in this mouse model and indicative of an AD-like pathology in orienting skills. Importantly, however, our finding that the prior alcohol

exposure impaired performance on the MWM memory probe trial in 3xTg-AD mice suggests that nondependent alcohol use may specifically target spatial memory and perception in vulnerable individuals. These results agree with recent evidence from a 30-year longitudinal cohort study in humans showing that long-term moderate alcohol drinking is associated with hippocampal atrophy (Tapiwala et al., 2017) and suggest that 3xTg-AD mice may show vulnerability to alcohol-induced pathology in the HPC.

3.4 Alcohol-induced deficit in sensorimotor processing

The startle reflex is an adaptive behavioral reflex that is elicited by sudden or loud stimuli. Prepulse inhibition (PPI) is a measure of sensorimotor gating where the startle reflex generated by a strong (e.g., loud) stimulus is inhibited by prior presentation of a weaker stimulus from the same sensory modality. Recent evidence indicates that patients with Alzheimer's dementia exhibit normal acoustic startle response but show reduced PPI as compared to healthy age-matched controls or patients with mild cognitive impairment (Ueki, Goto, Sato, Iso, & Morita, 2006). Accordingly, in the APP + PSEN-1 transgenic mouse model of AD, PPI was shown to be inversely related to A β expression in the cortex and HPC (Ewers, Morgan, Gordon, & Woodruff-Pak, 2006). It is not known if there is a relationship between alcohol use and sensorimotor gating in Alzheimer's disease.

To address this question, alcohol and saccharin exposed 3xTg-AD and WT controls were tested for PPI of the startle response. Results showed that saccharin exposed 3xTg-AD mice exhibited normal PPI, but a history of alcohol drinking was associated with a pronounced and significant impairment in PPI across a range of stimulus intensities (Fig. 5B). Three-way RM-ANOVA (alcohol $\times$ genotype $\times$ stimulus intensity, dB) with identified a significant main effect of both genotype [$F(1, 12) = 6.777, P = 0.023$] and dB [$F(3, 36) = 44.7, P < 0.0001$], and a significant alcohol $\times$ dB interaction [$F(1, 13) = 4.527, P = 0.038$].

These data indicate that a history of alcohol drinking by 3xTg-AD mice is associated with diminished PPI of the startle response. At the age tested (7–8 months), saccharin exposed 3xTg-AD mice did not exhibit altered PPI. This suggests that alcohol exacerbated the onset of cognitive dysfunction in the 3xTg-AD mouse model. PPI of the startle response is regulated by interconnected forebrain circuits including the PFC, entorhinal cortex, ganglia, HPC, and AMY (Swerdlow, Geyer, & Braff, 2001). Altered sensory processing is a common feature of AD and is consistent with recent evidence of PPI deficits linked to AD pathology in the lateral entorhinal cortex (LEC) of humans and mouse models (Khan et al., 2014). Indeed, entorhinal cortex lesions are associated with reduced PPI (Goto, Ueki, Iso, & Morita, 2002). However, deficits in PPI also underlie a variety of neuropsychiatric disorders including obsessive-compulsive disorder, schizophrenia, anxiety, and PTSD (Geyer & Swerdlow, 2001; Hoenig, Hochrein, Quednow, Maier, & Wagner, 2005; Kohl, Heekeren, Klosterkotter, & Kuhn, 2013) and may reflect diminished ability to filter or process relevant environmental stimuli. Thus, the alcohol-induced reduction in PPI may reflect the impact of extended alcohol drinking across a continuum of affective and neurological disorders in 3xTg-AD mice.

3.5 Alcohol-induced dysregulation of emotional processing in 3xTg-AD mice

Several studies have assessed cued and contextual fear conditioning in 6-month-old 3xTg-AD mice as measures of emotional and cognitive processing; however, results are inconsistent. One study reported increased freezing behavior by 3xTg-AD mice when exposed to a context previously paired with shock (Espana et al., 2010), which suggests intact associative memory with enhanced fear response. By contrast, another study reported reduced latency by 3xTg-AD mice to voluntarily enter a context previously paired with shock (Billings et al., 2005), which is consistent with reduced fear or emotional response and may reflect a hippocampal-dependent deficit in spatial memory. Alternatively, some studies have reported no difference between 3xTg-AD mice and WT controls on measures of cued or contextual fear conditioning (Chu, Giannopoulos, Ceballos-Diaz, Golde, & Pratico, 2012; Stover, Campbell, Van Winssen, & Brown, 2015a). In general, however, both the APP and 3xTg-AD mouse models of AD show associative memory deficits and emotional dysfunction (Billings et al., 2005; Gimenez-Llort et al., 2007; Saura et al., 2005) that are associated with A β pathology.

In the present study, cued and contextual fear conditioning were tested in 3xTg-AD and WT mice to assess the potential impact of a history of alcohol intake on emotional responding and associative memory. Results showed heightened freezing behavior by alcohol-exposed 3xTg-AD mice as compared to saccharin controls when presented with a cue that was previously paired with shock. No differences in freezing were observed when mice were exposed to the shock paired context (Fig. 5C). Although two-way ANOVA (alcohol $\times$ genotype) found no main effect for either variable and no interaction following both the cue and context test, a single planned comparison showed that 3xTg-AD mice with a history of alcohol drinking exhibited increased freezing behavior following exposure to the cue as compared to saccharin exposed 3xTg-AD mice ($t = 1.947$, $df = 6.076$, $P < 0.05$, Fig. 5C).

Anxiety and fear are common symptoms of neurodegenerative disorders including Alzheimer's disease (Chung & Cummings, 2000; Ferretti et al., 2001). Despite the well-known impact of alcohol on anxiety and emotional processing (Koob & Volkow, 2010), the influence of alcohol use on anxiety and fear associated with AD remains to be fully understood. The results of the present study show heightened cued fear response by 3xTg-AD mice with a history of alcohol intake. This suggests that nondependent alcohol use may dysregulate emotional responding in individuals vulnerable to, or in the early stages of, AD.

Moreover, cue-specific fear suggests altered AMY function (Phillips & LeDoux, 1992) and is consistent with known effects of alcohol and amygdala-based fear responses (Agoglia & Herman, 2018; McCool, Christian, Diaz, & Lack, 2010). The AMY also regulates positive reinforcing effects of alcohol (Besheer et al., 2003; Besheer, Fisher, Cannady, Grondin, & Hodge, 2012; Cannady et al., 2017; Salling et al., 2016; Schroeder et al., 2003) and cue-induced relapse to alcohol-seeking behavior (Cannady, Grondin, Fisher, Hodge, & Besheer, 2011; Salling et al., 2017; Schroeder et al., 2008), which suggests common neuroanatomical mechanisms of AD and alcohol addiction.

3.6 NIA-AA biomarker analysis in specific brain regions of 3xTg-AD mice (1-month post alcohol)

AD biomarkers including A β (40 and 42), Tau (total and pTau), in conjunction with imaging methods, can detect core features of AD and show promise for development of targeted therapeutics (Buckley et al., 2016; Jessen et al., 2014). As noted above, the NIA-AA Research Framework recommends a focus on these markers to enable a more accurate characterization and understanding of neural events that lead to AD-related cognitive and behavioral impairment (Jack et al., 2018). A recent meta-analysis of 51 peer-reviewed studies shows that neural expression of A β (40 and 42) and pTau (AT8—Ser181 and Ser199) exhibit strong associations with cognitive decline in the well-validated 3xTg-AD mouse model of AD that expresses human MAPT, APP, and PSEN-1 transgenes (Huber et al., 2018). Taken together with our neuroproteomic data show that alcohol-sensitive protein networks in the PFC and AMY are downstream of the MAPT, APP, and PSEN-1, this provides a strong rationale for evaluating the impact of alcohol intake on NIA-AA biomarkers in 3xTg-AD mice. Here, we evaluated NIA-AA biomarkers in specific brain regions of 3xTg-AD mice as a translational approach to increase understanding of the impact of alcohol drinking on the trajectory of neural pathology in AD.

3.6.1 Lateral entorhinal cortex (LEC)—Alcohol intake significantly increased A β (42/40) ratio [$t(7) = 4.1$, $P = 0.004$] and total Tau protein [$t(7) = 3.57$, $P = 0.009$] as compared to saccharin control (Fig. 6A). This pathology profile is consistent with *Alzheimer's disease and concomitant non-Alzheimer's pathologic change* (e.g., A + T – (N) +) because elevated total Tau, in the absence of pTau, may reflect general neuropathology (Table 2). Since the initial (mild) stage of AD is characterized by A β and Tau pathology in the LEC (Braak & Braak, 1998; Khan et al., 2014; Palmer et al., 2011), these results support the interpretation that alcohol drinking enhanced the onset of AD-like neural pathology in 3xTg-AD mice.

3.6.2 Prefrontal cortex (PFC)—Alcohol intake significantly increased the A β (42/40) ratio [$t(7) = 2.2$, $P = 0.03$], but had no effect on Tau expression (Fig. 6B). Elevated A β 42/40 ratio in the PFC is indicative of *Alzheimer's pathologic change* (e.g., A + T – (N)–) as reflected by amyloid pathology (Table 2), which is thought to occur at a (moderate) stage of AD (Braak & Braak, 1998); thus, alcohol drinking appears to enhance the onset of PFC-linked AD pathology in 3xTg-AD mice.

3.6.3 Medial prefrontal cortex (mPFC) and amygdala (AMY)—Alcohol had no effect on the A β (42/40) ratio in the mPFC or AMY. However alcohol drinking was associated with an increase in total Tau expression in both brain regions: mPFC—[$t(7) = 3.0$, $P = 0.02$] (Fig. 6C); AMY—[$t(7) = 3.6$, $P = 0.009$] (Fig. 6D). This result is consistent with *non-AD pathologic change* (e.g., A – T – (N)+, Table 2); however, Tau-related pathology is associated with late-stage AD suggesting that alcohol may exacerbate the onset of pathology in the AMY.

3.6.4 Additional brain regions—No changes in A β 42/40 ratio or total Tau protein were detected in samples from nucleus accumbens (Acb), medial hippocampus (MHPC),

lateral hippocampus (LHPC), CA1 subregion of the hippocampus (CA1), and the medial entorhinal cortex (MEC; data not shown).

3.6.5 Biomarker conclusions—*First*, based on evidence that 6–8-month-old 3xTg-AD mice exhibit AD-like pathology expressed as increased A β in the HPC, cortex, and AMY (Oddo, Caccamo, Shepherd, et al., 2003), these data suggest that alcohol increased the magnitude of AD-like pathology in the LEC and PFC during the initial cortical stages (e.g., Fig. 2). *Second*, 3xTg-AD mice are known to exhibit Tau pathology at 12–15 months; thus, the appearance of elevated total Tau in LEC, mPFC and AMY at 8 months of age suggests that alcohol drinking promoted rapid onset of pathology in these brain regions. *Third*, it is important to note that these data were obtained 1 month after alcohol use suggesting the presence of a long-term negative impact on AD-like pathology. Moreover, by focusing on biomarkers within the NIA-AA Research Framework, these findings integrate with the broader field of age-related neurodegeneration and suggest that alcohol use is a risk factor for AD-like pathology in vulnerable individuals. Increased knowledge of specific pathologies associated with alcohol use in AD has the potential to aid diagnosis and treatment.

3.7 Tau pathology: Hyperphosphorylation of Tau at GSK3 β site in 3xTg-AD mice (1-month post alcohol)

The presence of paired helical fragments formed by hyperphosphorylation of microtubule-associated protein Tau is a hallmark pathology of AD (Raskin, Cummings, Hardy, Schuh, & Dean, 2015). The Tau protein can be phosphorylated at a combined total of 85 serine, threonine, and tyrosine residues that constitute about 20% of the total protein (Tenreiro, Eckermann, & Outeiro, 2014); however, there appears to be specificity with respect to disease progression. In late-stage AD (Braak stage V/VI; Severe dementia, anxiety, depression) phosphorylation of a cluster of Tau residues termed AT8 (Ser199/Ser202/Thr205) is elevated in cortical brain tissue from human AD patients from 4- to 13-fold over controls (Neddens et al., 2018). Strikingly, analysis of the transentorhinal cortex showed that Tau phosphorylation at Ser199 was elevated as much as 160-fold over healthy controls suggesting a high degree of relevance for the Ser199 residue in disease progression (Neddens et al., 2018).

Although Tau is phosphorylated by numerous kinases, evidence indicates that glycogen synthase kinase-3 beta (GSK3 β) phosphorylation at Ser199 and Ser202 (pTau-Ser199/202) is a key component of AD pathology and thought to be a viable therapeutic target (Llorens-Martin, Jurado, Hernandez, & Avila, 2014). Interestingly, GSK3 β is an alcohol-sensitive gene (Wolen et al., 2012) and phosphoprotein (Cheng et al., 2017; Liu et al., 2017) in a variety of brain regions, including the HPC of adult mice exposed to prenatal alcohol (Cunningham et al., 2017). Therefore, we asked if Tau phosphorylation at the GSK3 β (Ser199/202) site is altered by alcohol drinking in 3xTg-AD mice, which would indicate a potential target of alcohol.

3xTg-AD and WT mice were sacrificed 1 month after alcohol or saccharin drinking (as described above) for qualitative assessment of pTau-Ser199/202 (pTau) immunoreactivity

(IR). pTau-Ser199/202 IR was not observed in WT mice (Fig. 7A). By contrast, alcohol produced pronounced hyperphosphorylation of Tau-Ser199/202 IR in dorsal hippocampal neuronal cell bodies and projections of 3xTg-AD mice as compared to saccharin controls (Fig. 7A). No difference was observed in BLA of 3xTg-AD mice (Fig. 7B).

The results of this study are consistent with prior findings in 3xTg-AD mice showing age-dependent increases in Tau AT8 expression. Untreated 3xTg-AD mice show low levels of pTau AT8 immunoreactivity the HPC (CA1 region) at 6months of age but prominent expression in neurons and projections at 15months of age (Oddo, Caccamo, Kitazawa, et al., 2003). This age-dependent progression of AT8 expression is similar to the present result showing that alcohol drinking (1-month post exposure) was associated with hyperphosphorylation of Tau at the Ser199/202 residues in the HPC. As noted above, Tau phosphorylation at these sites in humans is associated with advanced Braak stage V/VI Alzheimer's disease that is characterized by severe dementia and other neuropsychiatric symptoms. This raises the possibility that alcohol-induced upregulation of GSK3 β phosphorylation of Tau (Ser199/202) may mediate hippocampal-dependent behavioral pathology associated with alcohol use. Indeed, the present results show that alcohol-exposed 3xTg-AD mice have deficits in spatial memory (Fig. 5A) and sensorimotor gating (PPI, Fig. 5B), which are both modulated by hippocampal activity. It is also interesting to note that there was no difference in pTau (Ser199/202) IR in the BLA suggesting that apparent emotional dysregulation shown here in fear conditioning (Fig. 5C) is not related to pTau (Ser199/202) pathology. Elucidating the impact of alcohol use on Tau phosphorylation in the hippocampus has potential to move the field forward in understanding behavioral pathologies that occur in older individuals and may recommend therapeutic strategies for alleviation of specific cognitive deficits in patients with a history of alcohol use.

3.8 Analysis of Akt/mTOR phosphoprotein pathway throughout the brain after chronic alcohol: Decreased expression of multiple mTOR/Akt phosphoproteins in 3xTg-AD alcohol-exposed mice (1-month post alcohol)

To gain further understanding of the long-lasting impact of chronic nondependent alcohol drinking on molecular mechanisms of AD, we assessed the phosphorylation state of the Akt/mTOR cell signaling pathway. Akt/mTOR signaling regulates a wide array of molecular and cellular functions in the brain including nutrient uptake, glucose metabolism, cell growth and survival, transcription and migration (Yu & Cui, 2016). Importantly, the Akt/mTOR pathway is implicated in AD pathology in humans and animal models (Oddo, 2012) and alcohol addiction (Neasta, Barak, Hamida, & Ron, 2014). For example, glycogen synthase kinase-3 (GSK3) is critical to the hyperphosphorylation of Tau, has been linked to increased A β production, and A β mediated cell death (Avila et al., 2012; de la Monte et al., 1999; Hernandez, 2013; Hooper, Killick, & Lovestone, 2008). GSK3 also regulates the positive reinforcing effects of alcohol and is sensitive to acute alcohol treatment and withdrawal (Faccidomo et al., 2019; Neasta, Ben Hamida, Yowell, Carnicella, & Ron, 2011; van der Vaart et al., 2018). Additional proteins in the mTOR/Akt pathway such as Akt, PTEN, p70S6K, RPS6, ERK_{1/2} and mTOR are targets of interest in understanding the pathogenesis of AD as this cell signaling pathway is an important modulator of cell growth and macroautophagy maintaining a balance critical to the health of cells (Norambuena et al.,

2017; Pei & Hugon, 2008; Ro, Cao, Otto, & Kim, 2010). Overall, altered function of the Akt/mTOR pathway has been documented following acute and chronic alcohol exposure (Besheer et al., 2012; Faccidomo et al., 2015; Fu et al., 2016; Hagner et al., 2009; Neasta, Ben Hamida, Yowell, Carnicella, & Ron, 2010; Spanos, Besheer, & Hodge, 2012) and implicated in neural and behavioral pathology associated with neurodegeneration, suggesting that this cell signaling pathway may be a target of alcohol in the development and expression of AD.

In the present study, the brains of 3xTg-AD mice were probed for changes to phosphoproteins of the mTOR/Akt pathway after chronic, nondependent alcohol [(25%, w/v) + saccharin (0.1%, w/v) vs water (n = 5)] as compared to saccharin [(0.1%, w/v) vs water (n = 5)] drinkers in to our standard two-bottle choice 24-h home-cage method. Brains were removed approximately 1 month after the final alcohol or saccharin drinking session (at 8 months of age), so the following results indicate lasting changes provoked by the interaction of AD and chronic alcohol drinking. Both groups of mice drank similar volumes and alcohol drinking mice consumed an average of 15.7g/kg/day representing a moderate level of alcohol consumption, but not reaching binge or heavy drinking levels. Overall, the results indicate dysfunction of the mTOR/Akt phosphoprotein signaling with the predominate trend showing decreases throughout the brains of 3xTg-AD mice with a history of alcohol drinking.

3.8.1 Hippocampus—In three subregions of the HPC, (medial, lateral, and CA1) analyzed in this study, the effects on the mTOR/Akt pathway were subregion specific. This is an important distinction from other researchers looking at hippocampal changes as the subregion is not often specified. In the *MHPC*, no significant changes were observed in the expression of Akt/mTOR phosphoproteins between alcohol and saccharin exposed 3xTg-AD mice (Table 3). In the *LHPC*, a history of alcohol drinking in 3xTg-AD mice was associated with significant reductions in phosphorylation of IRS1 [$t(6) = 1.974$, $P = 0.048$] and P70S6K [$t(6) = 2.078$, $P = 0.042$] as compared to saccharin controls (Table 3). Finally, in *CA1*, a history of chronic alcohol drinking in 3xTg-AD mice was associated with a significant reduction in phosphorylated mTOR [$t(7) = 3.011$, $P = 0.01$] and PTEN [$t(7) = 3.021$, $P = 0.01$] as compared to saccharin controls (Table 3).

These results indicate that a history of alcohol drinking is associated with downregulation of Akt/mTOR phospho-signaling in subregions of the HPC in 3xTg-AD mice. The impact of alcohol was selective to the LHPC (IRS1 and p70S6K) and CA1 (mTOR and PTEN). This is consistent with evidence showing that levels of p-mTOR (Ser2448) and p70S6K (Thr389) are decreased in the cortex of double APP/PS1 transgenic mice as compared to WT controls (Lafay-Chebassier et al., 2005). Similarly, treatment of SH-SY5Y with 20 μ M A β decreases p-mTOR (Ser2448) expression, and pharmacological inhibition of mTOR induced cell death (Lafay-Chebassier et al., 2006). However, other reports show increased mTOR or PTEN in AD and mixed results in the alcohol literature (Caccamo, Belfiore, & Oddo, 2018; Fu et al., 2016; Griffin et al., 2005; Hagner et al., 2009; Li & Ren, 2007; Norambuena et al., 2017; Oddo, 2012; Tramutola et al., 2015; Wang et al., 2014). Thus, it will be critical for future studies to carefully parse out changes in these phosphoproteins due to AD pathology, long-term alcohol, and normal aging.

In the 3xTgAD mice, prior studies have found decreased levels of IRS-1 in the membrane fraction of hippocampal lysates (Ma et al., 2009). Moreover, phosphorylated IRS-1 is increased in 9-month-old 3xTg-AD mouse HPC and cortex but decreased at 10 and 15 months of age (Velazquez et al., 2017) when neural and behavioral pathology is most severe. Thus, the reduction in hippocampal IRS-1 phosphorylation seen in 8-month-old 3xTg-AD mice in the present study suggests that alcohol drinking may have exacerbated the onset or magnitude of AD-like pathology. This effect of alcohol was measured 1 month after exposure but is consistent with reduced IRS-1 phosphorylation seen after ethanol (100mM) in cell culture (Xu, Bhavani, Wands, & de la Monte, 1995).

In previous studies of AD, P70S6K is more often reported to be increased (An et al., 2003; Jin-Jing, 2008); however, alcohol has been reported to decrease P70S6K like it has been observed here (Hagner et al., 2009; Li & Ren, 2007), but to increase with acute exposure (Fu et al., 2016). Because this comparison is limited to saccharin or alcohol drinking 3xTg-AD mice, future studies will have to reconcile the differential effects on the phosphorylation of the P70S6K protein and the magnitude of the effects compared to wild-type mice.

3.8.2 Entorhinal cortex—The entorhinal cortex is sensitive to early AD pathology and this is reflected in both the brain and behavior. It is relevant in AD pathology in part because of a major pathway projecting from the AMY to the entorhinal (primarily lateral) as well as a substantial pathway projecting from the entorhinal cortex to the HPC. However, to date, the only study that has considered the role of the mTOR pathway in the AD pathology of the entorhinal cortex did so by pharmacologically inhibiting mTOR via chronic systemic treatment with rapamycin (Siman, Cocca, & Dong, 2015). This group observed a decrease in Tau-induced neuronal loss in the LEC, but not total Tau or mRNA levels. Our results suggest notable dysfunction of both the LEC and MED mTOR/Akt phosphoproteins after chronic alcohol consumption. In the LEC, alcohol drinking significantly decreased IGF1R [$t(8) = 1.905$, $P = 0.047$], IR [$t(8) = 2.211$, $P = 0.029$], and PTEN [$t(8) = 1.976$, $P = 0.042$]; while in the MEC, GSK3 α [$t(7) = 2.590$, $P = 0.018$], IGF1R [$t(7) = 2.949$, $P = 0.011$], IRS1 [$t(7) = 3.249$, $P = 0.007$], and RPS6 [$t(7) = 2.104$, $P = 0.037$] were all significantly reduced when compared to saccharin drinkers.

3.8.3 Amygdala—In the AMY, a history of alcohol drinking was associated with a significant decrease in pERK1/2/MAPT1/2 [$t(7) = 1.905$, $P = 0.049$]. No other significant changes were observed; however, trends toward a reduction were observed subregions of the HPC and entorhinal cortex (Table 3).

This finding is consistent with prior work showing that ERK1/2 phosphorylation is reduced in the AMY following alcohol withdrawal and associated with increased anxiety-like behavior in rats (Pandey et al., 2008). In the present study, 3xTg-AD showed a similar pattern of results with reduced pERK1/2 expression in the AMY associated with enhanced cued fear response. Thus, dysregulation of ERK1/2 activity in the AMY may mediate heightened anxiety and fear related to AD pathology. Other evidence, however, shows that pERK1/2 is increased in the AMY of APP_{Ind} transgenic mice immediately after cued fear conditioning, suggesting that ERK signaling regulates enhanced fear response associated with AD (España et al., 2010). Interestingly, the observed decrease in pERK1/2 observed in

the AMY of alcohol-exposed 3xTg-AD mice is similar to the effects of chronic unpredictable stress (Chandran et al., 2013). Thus, it will be important for future studies to evaluate pERK1/2 following cued fear conditioning in alcohol-exposed 3xTg-AD mice to determine if the observed basal downregulation is associated with insensitivity, or compensatory increased sensitivity, of ERK signaling under stressful conditions.

3.8.4 Conclusions—The mTOR/Akt pathway is critical in the regulation of cell growth, proliferation, and macroautophagy. The pathway is inextricably linked to aging and is regulated by growth factors, glucose, insulin, and stress. Aberrant signaling of the mTOR/Akt pathway has been implicated in human studies of AD and in numerous animal models, though the literature isn't consistent about specific increases or decreases of total or phosphorylated proteins. To account for this discrepancy, it has been proposed that Akt/mTOR phosphorylation is decreased in neurons that are sensitive to AD and increased or maintained in neurons that are insensitive to AD (Pei & Hugon, 2008). Consistent with this premise, the present study found evidence for no change, significant decreases, and trends for increased phosphorylation in the Akt/mTOR pathway that was protein- and brain region-dependent. Moreover, the present study evaluated phosphorylation of Akt/mTOR signaling proteins in relatively young 3xTg-AD mice (8 months of age) at 1-month after alcohol exposure, which may reflect direct long-lasting effects of alcohol or compensatory changes. For these reasons, we suggest that understanding the impact of alcohol drinking on the Akt/mTOR signaling pathway in AD will require delineation of age-, time-, and brain region-dependent effects of alcohol. It is plausible that vulnerability to AD-like neural and behavioral pathology will vary as a function of one or more of these variables.

Likewise, the Akt/mTOR pathway is both directly and indirectly impacted by alcohol consumption via its direct inhibition of IRS1, and indirectly through modulation of metabolic function. It is for these reasons invariably complicated to study the interaction of AD and alcohol consumption on the mTOR/Akt pathway, but also imperative. The ability of multiple proteins in the mTOR/Akt pathway to directly affect the production of AB and hyperphosphorylation of Tau makes it a potential therapeutic target for early disease.

4. General discussion

Alcohol use impacts health and disease across the lifespan. Especially relevant to the aging population, emerging evidence suggests that alcohol use is a potential risk factor for AD and other forms of dementia. The purpose of the present study was to test aspects of the overall hypothesis that alcohol use exacerbates the onset and magnitude of AD-like pathology.

The scientific premise of this work was based primarily on our prior analysis of the neuroproteome that revealed a striking, and unanticipated, major association between alcohol and AD pathology in C57BL/6J mice (Agoglia & Hodge, 2017; Salling et al., 2016). A newly conducted bioinformatics analysis of those data identified three primary mechanisms of AD (MAPT, PSEN-1, and APP proteins) as the statistically most likely upstream modulators of alcohol-sensitive protein networks in the PFC and amygdala. Based on this predicted relationship, we sought to evaluate the impact of voluntary nondependent alcohol drinking on AD-like neural and behavioral pathologies in the 3xTg-AD mouse

model of AD, which expresses human MAPT, PSEN-1, and APP transgenes (Oddo, Caccamo, Shepherd, et al., 2003).

4.1 Alcohol-induced behavioral deficits

As noted above, AD is characterized by a progressive decline in cognition (e.g., memory, stimulus processing) and other behavioral functions (e.g., anxiety, fear). Importantly, cognitive decline in conjunction with comorbid neuropsychiatric conditions such as anxiety may reflect early stages of AD pathology (Buckley et al., 2016; Jessen et al., 2014). Evidence indicates that 3xTg-AD mice exhibit a variety of behavioral phenotypes consistent with progressive cognitive decline and altered emotional state in a manner that is associated with development of underlying neural pathology (Filali et al., 2012; Huber et al., 2018; Pietropaolo et al., 2014; Romano et al., 2014; Webster et al., 2014).

The behavioral test battery used in the present study showed that a history of alcohol drinking (4-months) was associated with deficits in 3xTg-AD mice as compared to saccharin exposed and WT controls. As discussed above, 3xTg-AD mice, and other mouse models of AD, develop age-dependent pathologies in these behavioral domains irrespective of alcohol exposure (Webster et al., 2014). However, at the age range tested (7–8 months) saccharin exposed 3xTg-AD mice in the present study did not show major behavioral abnormalities as compared to wild-type controls with the only notable deficit appearing in spatial learning in Morris Water Maze (e.g., acquisition). By contrast, a history of nondependent alcohol drinking produced behavioral deficits in spatial memory as tested in the Morris Water Maze (probe trial), sensorimotor gating (PPI of the startle response), and emotional processing as indexed by enhanced cued fear response.

Both male and female mice were tested in the present study, but sample size did not allow statistical evaluation of sex as a biological variable. That said, we observed tendencies for sex-based differences in Morris Water Maze and prepulse inhibition performance with female data trending toward a greater deficit. This raises the possibility that females may show enhanced vulnerability to the age-dependent effects of alcohol on cognitive function. However, results also showed a trend for female mice to consume higher doses of alcohol than males, which is consistent with evidence from a wide sample of rodent studies (Becker & Koob, 2016); thus, it will be necessary in future preclinical studies to equate alcohol intake between sexes using between group yoking procedures. In addition, sex-based differences in alcohol pharmacokinetics may account for differential neural or behavioral effects, which complicates direct dose-dependent comparisons. Nevertheless, it is important to note that the impact of alcohol on cognitive (memory) function in older adults is more pronounced in women (Lewis et al., 2019) underscoring the importance of conducting future preclinical work to elucidate neural mechanisms that might contribute to female vulnerability.

Overall, these data show that voluntary alcohol drinking in 3xTg-AD mice is associated with impaired cognitive and emotional functions as compared to saccharin and wild-type controls, which mimic behavioral pathologies seen in humans with AD and suggest that alcohol exacerbated the onset of these symptoms. However, there remains a gap in knowledge regarding the sex- and age-dependent impact of alcohol use on AD-like

pathology in older individuals. To address this question, future preclinical studies could evaluate the impact of alcohol exposure in 3xTg-AD mice at timepoints that correspond pre- and post-pathology phases of development in male and female mice.

4.2 Impact of alcohol on AD biomarkers in specific brain regions

As discussed above, the jointly proposed NIA-AA Research Framework calls for a biological definition of AD with emphasis on categorizing AD pathology based on measurement of specific biomarkers including A β , Tau, neurodegeneration, and cognitive symptoms (Jack et al., 2018). In this framework, specific combinations of individual measures have different interpretations. Presence of A β biomarkers (e.g., the A β 42/40 ratio) determines presence on the Alzheimer's continuum (Table 2). Pathologic tau biomarkers (e.g., pTau) can indicate non-AD pathology if detected in isolation; however, combined A β and Tau biomarkers indicates presence of AD because both are required for diagnosis of the disease. The addition of cognitive symptoms is also used for disease staging with dementia (e.g., cognitive impairment in several domains with additional behavioral symptoms) indicating the most severe stage (Jack et al., 2018). In this study, we took a translational approach and evaluated AD biomarkers within specific brain regions of the 3xTg-AD mice and evaluated the results in the context of the NIA-AA framework.

Results from the present preclinical study indicate that a history of alcohol exposure is associated with a biomarker profile that is consistent with alcohol-induced expression of Alzheimer's disease in 3xTg-AD mice. First, alcohol exposure resulted in an increase in the A β (42/40) ratio in the LEC and PFC (Fig. 6A and B). A β (42) is the toxic form of A β and is upregulated in postmortem brains of AD patients. This results in an A+ categorization and is indicative of presence on the AD continuum (Table 2). Second, we observed an increase in total Tau protein expression in the LEC, mPFC and AMY. An increase in total Tau protein is indicative of neurodegeneration or neuronal injury and represents an N+ categorization. These data indicate that alcohol use was associated with an A + T(N)+ combination, which indicates Alzheimer's and concomitant non-Alzheimer's pathology in the LEC, which is an initial anatomical target of AD pathology (Table 2). In addition, immunohistochemistry was used to measure pTau expression. Qualitative results showed a prominent upregulation of pTau (Ser199/202) in the hippocampus (CA1) of alcohol-exposed 3xTg-AD mice. Taken together across brain regions, these data suggest that alcohol exposure produced an A + T + (N)+ biomarker profile, which is consistent with Alzheimer's disease.

It is a limitation of the present study that we did not measure pTau in the multiplex immunoassay. This was due to a limitation of the technique, which could not differentiate and count individual microbeads labeled with pTau due to excessive protein aggregation and bead clustering. Methodological development efforts are underway in our laboratory with the goal of disaggregating pTau prior to measurement; however, future studies will utilize immunoblot or immunohistochemistry approaches to obtain pTau measurements across the brain.

Overall, these results suggest that alcohol use is a modifiable risk factor for AD. By focusing on AD biomarkers within the NIA-AA Research Framework, this work integrates with the broader field of age-related neurodegeneration and extends efforts to elucidate the impact of

alcohol age-related neurodegeneration. Increased knowledge of specific pathologies associated with alcohol use in AD has potential to aid diagnosis and treatment.

4.3 Alcohol-induced hyperphosphorylation of Tau in the hippocampus

As noted above, glycogen synthase kinase 3 (GSK3) is a serine-threonine kinase that is expressed in the mammalian brain system in two isoforms, GSK3 α and GSK3 β (Woodgett, 1990). Dysregulated GSK3 β activity is associated with several neurological and neuropsychiatric diseases including Alzheimer's (Cai, Zhao, & Zhao, 2012) and is thought to serve as a molecular link between A β and Tau pathology (Llorens-Martin et al., 2014). GSK3 β cleaves APP to A β and directly phosphorylates Tau at multiple amino acid residues including Ser199/Ser202. Acute and chronic alcohol exposure is known to increase GSK3 β phosphorylation (Neasta et al., 2014, 2010, 2011; van der Vaart et al., 2018) but the long-term effects of alcohol use on GSK3 activity and function remain to be elucidated. Results from this study show that a history of alcohol use (1-month post alcohol) is associated with hyperphosphorylation at the GSK3 site on Tau (Ser199/Ser202) in hippocampus (CA1) subregion of 3xTg-AD mouse brain.

The heightened pTau (Ser199/202) immunoreactivity observed in 3xTg-AD mice suggests that nondependent alcohol use may produce enduring changes in the functional effects of GSK3 that underly neural pathology. Moreover, GSK3 may represent a therapeutic target for neurodegeneration associated with alcohol use or abuse. A growing literature indicates that pharmacological or genetic inhibition of GSK3 blocks cleavage of APP, which reduces A β deposits and restores hippocampal-dependent spatial memory (water maze) in mice (King et al., 2014; Ly et al., 2013; Rockenstein et al., 2007). Similarly, chronic GSK3 β inhibition reduces Tau phosphorylation and improves memory in 3xTg-AD mice (Huang et al., 2019). Although GSK3 inhibitors have produced mixed results in clinical trials, selective non-ATP competitive compounds are well-tolerated in vivo and serve as useful experimental tools to probe mechanism of action and may have therapeutic efficacy under specific pathological conditions. For example, non-ATP competitive TDZD derivative tideglusib (200mg/kg, p.o. for 3months) reduces AD-like pathology in mice including decreased Tau phosphorylation and A β deposition in the entorhinal cortex and HPC (CA1) with associated prevention of memory deficits in the Morris Water Maze (Serenio et al., 2009). More research is needed to determine if GSK3 inhibition modulates Tau pathology seen following alcohol exposure.

4.4 Impact of alcohol use on the Akt/mTOR pathway

Results of this study showed a general downregulation of multiple Akt/mTOR phosphoproteins in AMY, LHPC, CA1, LEC, and MEC suggesting that a history of alcohol use produced an enduring general disruption of Akt/mTOR signaling in brain regions associated with AD pathology. As noted above, the Akt/mTOR signaling pathway regulates cell growth and proliferation, as well as macroautophagy. Given the neurodegenerative nature of AD and chronic alcohol consumption, it is not unexpected that together they would disrupt these basic processes and, potentially, accelerate decline. However, the mechanisms that are specifically responsible are harder to understand as the nature of phosphorylated proteins is only one change in response to environmental demands on both a micro and macro scale in any signaling pathway.

GSK3 is a key member of the Akt/mTOR cell signaling pathway. Given the upregulation of pTau (Ser199/202) immunoreactivity observed in CA1, we predicted that alcohol use would be associated with altered GSK3 phosphorylation in this brain region. However, alcohol exposure was associated with trends for increased GSK3 α (Ser21) and decreased GSK3 β (Ser9) phosphorylation in CA1. Since GSK3 α activity is increased by phosphorylation and GSK3 β activity is increased by dephosphorylation, these trends in phosphorylation may have been enough to support increased Tau phosphorylation. Further work is needed to determine if alcohol-induced changes in GSK3 phosphorylation modulate Tau phosphorylation and expression of AD-like pathology.

Understanding the delicate balance of the various proteins in the Akt/mTOR pathway in relation to alcohol's impact on AD could ultimately provide novel targets for therapeutic strategies that are able to restore balance rather than simply increase or decrease specific proteins. It should also be acknowledged that there is a need for future studies to consider the impact of changes in the periphery (i.e., liver, pancreas) on the CNS. Changes in the brain, especially to regulatory processes, result in changes in the periphery that can in turn act as a feedback loop to result in further changes to the regulatory processes in the brain. Alcohol is well known to have detrimental impact on various organs and these changes in metabolism and insulin regulation are more than likely also factors that need to be considered when studying the CNS mTOR/Akt pathway in the context of AD and long-term alcohol consumption.

4.5 Alcohol-induced impact on the neuroproteome and AD

It is noteworthy that many of the alcohol-sensitive proteins that were significantly changed in our proteomic networks are also associated with major neurodegenerative diseases such as AD and schizophrenia (Hensley, Venkova, Christov, Gunning, & Park, 2011; Martins-De-Souza et al., 2010). The DPYSL protein, which was significantly downregulated in the amygdala network, stands out for many reasons and may be an ideal therapeutic target for AD. The gene DPYSL encodes a protein called collapsin response mediator protein 2 (CRMP2) which is a member of a family of CRMP proteins that regulate microtubule formation and axonal growth (Charrier et al., 2003). CRMP is highly expressed in the CNS and it is important for microtubule formation and stability, vesicle trafficking and ion channel stability, among other functions. There has been exponential interest in the functional role of this protein in disease pathology because it is hyperphosphorylated in the brains of both AD patients and it is known to be a key phosphorylation substrate for GSK3 β , CDK5 and CAMKII (Soutar, Thornhill, Cole, & Sutherland, 2009). Phosphorylation of CRMP at these sites renders it unable to function properly and is proximally associated with plaque and tangle formations in AD brains (Yoshida, Watanabe, & Ihara, 1998). Further, it has been shown that CRMP2 co-aggregates with Tau in 3xTg mice at an early age, suggesting that CRMP could be used as an early biomarker for AD, prior to expression of significant behavioral deficits (Cole et al., 2007).

Our behavioral data suggest that 3xTg mice show impaired spatial learning (MWM acquisition) by 7–8months of age and that a history of moderate alcohol drinking leads to impaired short-term spatial memory (probe test). Likewise, CRMP1 KO mice show

decreased LTP in CA1 and impaired acquisition of spatial learning in the Morris Water Maze as well as impaired short-term memory on a probe (Su et al., 2007). Together, these data suggest that the CRMP family of proteins may regulate some of the behavioral deficits that are observed in 3xTg mice with high likelihood of contributing to the molecular deficits. Because of its potential usefulness as an early biomarker for AD, CRMP may be a logical therapeutic target for reversing or mitigating some of the pathological and behavioral deficits associated with AD. Indeed, this hypothesis was tested by Hensley and colleagues in 3xTg mice (Hensley et al., 2013). They administered a drug that binds to CRMP2 and found that it diminished the consequences of disease progression as measured by decreased latency to find a platform in the MWM and a decrease in AB and APP immunoreactivity in the HPC. Alternatively, pharmacologically increasing expression of CRMP2 has been proposed as a possible therapeutic because it could counteract the neuronal stress associated with AD. The atypical anti-depressant, tianeptine, has a multitude of pharmacological actions, and mechanistically, it has been shown to interfere with CAMKII-GluA1 binding and pharmacologically increase CRMP expression (Hensley et al., 2011). This drug is widely prescribed for depression, yet its mechanisms of action suggest that it could be an effective candidate for the treatment of AD. Importantly, we have recently published evidence that CRMP is more abundant in the adult vs adolescent PFC proteome (Agoglia et al., 2017), we show here that CRMP is downregulated by alcohol drinking and pharmacological treatment with tianeptine can indeed reduce levels of binge drinking in adult mice (Agoglia, Sharko, et al., 2015). Future studies might investigate whether tianeptine could be effective in reversing and/or ameliorating the AD behavioral and brain pathology induced by chronic alcohol drinking.

A striking commonality of the alcohol-sensitive proteins that were upregulated in the mPFC and AMY is their notable relevance to AD pathology. Creatine kinase B (CKB), hexokinase (HK1), syntaxin binding protein 1 (STXB1/MUNC-18), amphiphysin (AMPH), complexin, and heat shock proteins are all upregulated in the cortex of AD patients and in normal, alcohol-drinking C57BL/6J mice (Donovan et al., 2012; Jacobs, Williams, & Francis, 2006; Lynn, Wang, Markesbery, & Lovell, 2010; Rivera et al., 2018). Further, CKB and HK1 are more prominently increased in the brains of individuals with early- vs late-stage disease suggesting that proteins relevant for energy use and metabolism may be early markers of brain pathology and stress. Munc-18 and complexin are part of a family of neuronal vesicular proteins regulating the SNARE complex which is involved in rapid exocytosis and neurotransmitter release at neuronal synapses (Pabst et al., 2002; Sudhof, 2013; Tang et al., 2006). Mechanistically, this complex directly binds to APP causing increased aggregation of A β in the brain and indeed, these proteins are physically located in proximity to aggregated A β (Chaufy, Sullivan, & Ho, 2012; Jensen, Albertsen, Bartling, Haugaard-Kedstrom, & Stromgaard, 2018).

Thus, although alcohol drinking induced differential changes in the PFC and AMY proteome, specific target proteins in each brain region are known to regulate aspects AD pathology. Moreover, identified networks or protein groupings were identified by IPA as likely to be downstream of APP, PSEN-1 and Tau, which suggests collective involvement of unique protein networks within the PFC and AMY in AD. This indicates that alcohol use may influence AD pathology via distinct but functionally related protein networks that vary

across brain regions. Therefore, efforts to more fully elucidate the impact of alcohol use on AD will benefit from a systems approach that delineates adaptations in specific molecular mechanisms within brain regions, but also takes into account common functional effects of distinct proteins between brain regions.

4.6 Conclusions and future directions

Alcoholism and Alzheimer's disease are both neuroinflammatory and neurodegenerative disorders and as such, may share an overlapping etiology. The data show that indeed, the neuropathological changes that are associated with both disorders can be linked to mechanisms related to AB, Tau and the mTOR pathway. The relevance of our alcohol proteomic networks to AD indicate that there may be important systems that could be useful early biomarkers (CRMP, HSK, AMPH, GSK) for identifying at-risk populations that could be then targeted with medications (tianeptine, lacosamide, tideglusib) with prophylactic treatment to prevent or minimize the development of AD. Given the strength of these associations, further research in both clinical and preclinical populations to test these hypotheses is warranted. Together, these data strongly suggest that some (or all) of these molecular mechanisms may be dysregulated by moderate alcohol use and that this may increase risk for developing and or exacerbating AD in susceptible populations.

Preclinical strategies, such as those reported here, allow collection of new and important data implicating a maladaptive role for alcohol in the neuropathological and behavioral developmental trajectory of AD. The 3xTg-AD mouse, and other models of AD, provide a unique opportunity to investigate how alcohol, and other modifiable risk factors, interact with mechanisms of AD and have potential to lead to synergistic discoveries that span research fields focused on age-dependent and drug-induced neurodegeneration. A potential future direction from these studies is to address mechanistic regulation by specific proteins, brain regions, and/or neural circuits. This could be accomplished by site-specific pharmacological, AAV, and optogenetic strategies. One circuit that might be important to evaluate is the projection from the lateral entorhinal cortex to the CA1 region of the HPC. The CA1 subregion shows intrinsic and circuit heterogeneity that may underlie the involvement of this structure in AD-associated behavioral pathologies (Masurkar, 2018); thus, subregional and circuit analyses have potential to identify specific anatomical substrates of alcohol's impact on AD. Given the involvement of these brain regions in the onset of AD-like pathology, attenuating activity of this pathway may block or enhance disease state. Future studies might also pursue alcohol-induced instability of the Alzheimer's-linked neural proteome or assess other mouse models of the disease. Additional approaches such as rodent fMRI to assess functional connectivity among AD target brain regions may also reveal novel neural pathways and mechanisms that are targeted by alcohol in AD-vulnerable or AD-expressing populations. Mechanistic studies are highly difficult, or even improbable, to conduct in human subjects; thus, further underscoring the value of having a well-characterized mouse model of AD to evaluate the impact of alcohol use on disease progression. Overall, mouse models of AD offer a novel and an exciting approach to assess the impact of alcohol use on neurodegeneration and represent an opportunity to identify novel therapeutic targets that could have long-lasting beneficial health consequences for the elderly population.

Acknowledgments

This research was supported by NIAAA grants R37AA014983, R37AA014983S1 and P60AA011065 to C.W.H. and by the UNC Bowles Center for Alcohol Studies. Mouse behavioral tests were conducted in the UNC Mouse Behavioral Core with assistance from Dr. Sheryl Moy supported by NICHD grant U54 HD079124. All authors declare that they have no conflict of interest.

References

- Agoglia AE, & Herman MA (2018). The center of the emotional universe: Alcohol, stress, and CRF1 amygdala circuitry. *Alcohol*, 72, 61–73. [PubMed: 30220589]
- Agoglia AE, & Hodge CW (2017). Alcohol-induced alterations in the adolescent mouse prefrontal cortex proteome identify cannabinoid signaling as a mechanism of vulnerability to alcohol abuse. *Alcoholism, Clinical and Experimental Research*, 41, 202.
- Agoglia AE, Holstein SE, Eastman VR, & Hodge CW (2016). Cannabinoid CB1 receptor inhibition blunts adolescent-typical increased binge alcohol and sucrose consumption in male C57BL/6J mice. *Pharmacology, Biochemistry, and Behavior*, 143, 11–17.
- Agoglia AE, Holstein SE, Reid G, & Hodge CW (2015). CaMKIIalpha-GluA1 activity underlies vulnerability to adolescent binge alcohol drinking. *Alcoholism, Clinical and Experimental Research*, 39, 1680–1690.
- Agoglia AE, Holstein SE, Small AT, Spanos M, Burrus BM, & Hodge CW (2017). Comparison of the adolescent and adult mouse prefrontal cortex proteome. *PLoS One*, 12, e0178391. [PubMed: 28570644]
- Agoglia AE, Sharko AC, Psilos KE, Holstein SE, Reid GT, & Hodge CW (2015). Alcohol alters the activation of ERK1/2, a functional regulator of binge alcohol drinking in adult C57BL/6J mice. *Alcoholism, Clinical and Experimental Research*, 39, 463–475.
- Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 7, 270–279.
- Alzheimer's-Association. (2016). 2016 Alzheimer's disease facts and figures. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 12, 459–509.
- Alzheimer's-Association. (2019). 2019 Alzheimer's disease facts and figures. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 15, 321–387.
- An W-L, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, et al. (2003). Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. *The American Journal of Pathology*, 163, 591–607. [PubMed: 12875979]
- Avila J, León-Espinosa G, García E, García-Escudero V, Hernández F, & Defelipe J (2012). Tau phosphorylation by GSK3 in different conditions. *International Journal of Alzheimer's Disease*, 2012, 578373.
- Ballatore C, Lee VM, & Trojanowski JQ (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nature Reviews Neuroscience*, 8, 663–672. [PubMed: 17684513]
- Becker JB, & Koob GF (2016). Sex differences in animal models: Focus on addiction. *Pharmacological Reviews*, 68, 242–263. [PubMed: 26772794]
- Benilova I, Karran E, & De Strooper B (2012). The toxic Aβ oligomer and Alzheimer's disease: An emperor in need of clothes. *Nature Neuroscience*, 15, 349–357. [PubMed: 22286176]
- Besheer J, Cox AA, & Hodge CW (2003). Coregulation of ethanol discrimination by the nucleus accumbens and amygdala. *Alcoholism, Clinical and Experimental Research*, 27, 450–456.
- Besheer J, Fisher KR, Cannady R, Grondin JJ, & Hodge CW (2012). Intra-amygdala inhibition of ERK(1/2) potentiates the discriminative stimulus effects of alcohol. *Behavioural Brain Research*, 228, 398–405. [PubMed: 22209853]
- Besheer J, & Hodge CW (2005). Pharmacological and anatomical evidence for an interaction between mGluR5- and GABA(A) α1-containing receptors in the discriminative stimulus effects of ethanol. *Neuropsychopharmacology*, 30, 747–757. [PubMed: 15549054]

- Besheer J, Lepoutre V, Mole B, & Hodge CW (2006). GABAA receptor regulation of voluntary ethanol drinking requires PKCepsilon. *Synapse*, 60, 411–419. [PubMed: 16881070]
- Billings LM, Oddo S, Green KN, McGaugh JL, & LaFerla FM (2005). Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. *Neuron*, 45, 675–688. [PubMed: 15748844]
- Bittner N, Jockwitz C, Muhleisen TW, Hoffstaedter F, Eickhoff SB, Moebus S, et al. (2019). Combining lifestyle risks to disentangle brain structure and functional connectivity differences in older adults. *Nature Communications*, 10, 621.
- Braak H, & Braak E (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathologica*, 82, 239–259. [PubMed: 1759558]
- Braak H, & Braak E (1998). Evolution of neuronal changes in the course of Alzheimer's disease. *Journal of Neural Transmission. Supplementum*, 53, 127–140. [PubMed: 9700651]
- Breslow RA, Castle IP, Chen CM, & Graubard BI (2017). Trends in alcohol consumption among older Americans: National Health Interview Surveys, 1997 to 2014. *Alcoholism, Clinical and Experimental Research*, 41, 976–986.
- Buckley RF, Villemagne VL, Masters CL, Ellis KA, Rowe CC, Johnson K, et al. (2016). A conceptualization of the utility of subjective cognitive decline in clinical trials of preclinical Alzheimer's disease. *Journal of Molecular Neuroscience*, 60, 354–361. [PubMed: 27514526]
- Caccamo A, Belfiore R, & Oddo S (2018). Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer's disease. *Neurobiology of Aging*, 68, 59–67. [PubMed: 29729422]
- Cai Z, Zhao Y, & Zhao B (2012). Roles of glycogen synthase kinase 3 in Alzheimer's disease. *Current Alzheimer Research*, 9, 864–879. [PubMed: 22272620]
- Cannady R, Fisher KR, Graham C, Crayle J, Besheer J, & Hodge CW (2017). Potentiation of amygdala AMPA receptor activity selectively promotes escalated alcohol self-administration in a CaMKII-dependent manner. *Addiction Biology*, 22, 652–664. [PubMed: 26742808]
- Cannady R, Grondin JJ, Fisher KR, Hodge CW, & Besheer J (2011). Activation of group II metabotropic glutamate receptors inhibits the discriminative stimulus effects of alcohol via selective activity within the amygdala. *Neuropsychopharmacology*, 36, 2328–2338. [PubMed: 21734651]
- Chandran A, Iyo AH, Jernigan CS, Legutko B, Austin MC, & Karolewicz B (2013). Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 40, 240–245. [PubMed: 22889863]
- Chang RY, Nouwens AS, Dodd PR, & Etheridge N (2013). The synaptic proteome in Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 9, 499–511.
- Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, & Honnorat J (2003). Collapsin response mediator proteins (CRMPs): Involvement in nervous system development and adult neurodegenerative disorders. *Molecular Neurobiology*, 28, 51–64. [PubMed: 14514985]
- Chaufy J, Sullivan SE, & Ho A (2012). Intracellular amyloid precursor protein sorting and amyloid-beta secretion are regulated by Src-mediated phosphorylation of Mint2. *The Journal of Neuroscience*, 32, 9613–9625. [PubMed: 22787047]
- Cheng Y, Huang CCY, Ma T, Wei X, Wang X, Lu J, et al. (2017). Distinct synaptic strengthening of the striatal direct and indirect pathways drives alcohol consumption. *Biological Psychiatry*, 81, 918–929. [PubMed: 27470168]
- Cherrier MM, Mendez M, & Perryman K (2001). Route learning performance in Alzheimer disease patients. *Neuropsychiatry, Neuropsychology, and Behavioral Neurology*, 14, 159–168.
- Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, & Pratico D (2012). 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. *Annals of Neurology*, 72, 442–454. [PubMed: 23034916]
- Chung JA, & Cummings JL (2000). Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: Characteristics and treatment. *Neurologic Clinics*, 18, 829–846. [PubMed: 11072263]

- Cole AR, Noble W, van Aalten L, Plattner F, Meimaridou R, Hogan D, et al. (2007). Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. *Journal of Neurochemistry*, 103, 1132–1144. [PubMed: 17683481]
- Cunningham LA, Newville J, Li L, Tapia P, Allan AM, & Valenzuela CF (2017). Prenatal alcohol exposure leads to enhanced serine 9 phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) in the hippocampal dentate gyrus of adult mouse. *Alcoholism, Clinical and Experimental Research*, 41, 1907–1916.
- de la Monte SM, Ganju N, Tanaka S, Banerjee K, Karl PJ, Brown NV, et al. (1999). Differential effects of ethanol on insulin-signaling through the insulin receptor substrate-1. *Alcoholism: Clinical and Experimental Research*, 23, 770–777.
- Donovan LE, Higginbotham L, Dammer EB, Gearing M, Rees HD, Xia Q, et al. (2012). Analysis of a membrane-enriched proteome from postmortem human brain tissue in Alzheimer's disease. *Proteomics. Clinical Applications*, 6, 201–211. [PubMed: 22532456]
- Espana J, Gimenez-Llort L, Valero J, Minano A, Rabano A, Rodriguez-Alvarez J, et al. (2010). Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. *Biological Psychiatry*, 67, 513–521. [PubMed: 19664757]
- Ewers M, Morgan DG, Gordon MN, & Woodruff-Pak DS (2006). Associative and motor learning in 12-month-old transgenic APP+PS1 mice. *Neurobiology of Aging*, 27, 1118–1128. [PubMed: 15993985]
- Faccidomo S, Holstein SE, Santanam TS, Saunders BL, Swaim KS, Reid GT, et al. (2019). Pharmacological inhibition of glycogen synthase kinase 3 increases operant alcohol self-administration in a manner associated with altered pGSK-3 β , PICK1 and GluA2 protein expression in the reward pathway of male C57BL/6J mice. *Behavioural Pharmacology*. 10.1097/FBP.0000000000000501. (Epub ahead of print).
- Faccidomo S, Reid GT, Agoglia AE, Ademola SA, & Hodge CW (2016). CaMKII inhibition in the prefrontal cortex specifically increases the positive reinforcing effects of sweetened alcohol in C57BL/6J mice. *Behavioural Brain Research*, 298, 286–290. [PubMed: 26608538]
- Faccidomo S, Salling MC, Galunas C, & Hodge CW (2015). Operant ethanol self-administration increases extracellular-signal regulated protein kinase (ERK) phosphorylation in reward-related brain regions: Selective regulation of positive reinforcement in the prefrontal cortex of C57BL/6J mice. *Psychopharmacology*, 232, 3417–3430. [PubMed: 26123321]
- Faccidomo S, Swaim KS, Saunders BL, Santanam TS, Taylor SM, Kim M, et al. (2018). Mining the nucleus accumbens proteome for novel targets of alcohol self-administration in male C57BL/6J mice. *Psychopharmacology*, 235, 1681–1696. [PubMed: 29502276]
- Ferretti L, McCurry SM, Logsdon R, Gibbons L, & Teri L (2001). Anxiety and Alzheimer's disease. *Journal of Geriatric Psychiatry and Neurology*, 14, 52–58. [PubMed: 11281317]
- Filali M, Lalonde R, Theriault P, Julien C, Calon F, & Planel E (2012). Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated APP, PS1, and Mapt (3xTg-AD). *Behavioural Brain Research*, 234, 334–342. [PubMed: 22796601]
- Franceschi C, Garagnani P, Morsiani C, Conte M, Santoro A, Grignolio A, et al. (2018). The continuum of aging and age-related diseases: Common mechanisms but different rates. *Frontiers in Medicine*, 5, 61. [PubMed: 29662881]
- Franklin KBJ, & Paxinos G (2001). *The mouse brain in stereotaxic coordinates* (2nd ed.). New York: Academic Press.
- Fu X, Guo Z, Gao C, Chu Q, Li J, Ma H, et al. (2016). Long-term alcohol-induced activation of mammalian target of rapamycin is a key risk factor of epilepsy. *Medical Science Monitor*, 22, 3975–3980. [PubMed: 27779177]
- Fu Y, Zhao D, Pan B, Wang J, Cui Y, Shi F, et al. (2015). Proteomic analysis of protein expression throughout disease progression in a mouse model of Alzheimer's disease. *Journal of Alzheimer's Disease: JAD*, 47, 915–926. [PubMed: 26401771]
- Games D, et al. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein. *Nature*, 373, 523–527. [PubMed: 7845465]

- Garvock-de Montbrun T, Fertan E, Stover K, & Brown RE (2019). Motor deficits in 16-month-old male and female 3xTg-AD mice. *Behavioural Brain Research*, 356, 305–313. [PubMed: 30208295]
- Geyer MA, & Swerdlow NR (2001). Measurement of startle response, prepulse inhibition, and habituation. *Current Protocols in Neuroscience*, Chapter 8 Unit 8.7.
- Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. (2003). Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. *Neurology*, 60, 1495–1500. [PubMed: 12743238]
- Gimenez-Llort L, Blazquez G, Canete T, Johansson B, Oddo S, Tobena A, et al. (2007). Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: A role for intraneuronal amyloid. *Neuroscience and Biobehavioral Reviews*, 31, 125–147. [PubMed: 17055579]
- Goto K, Ueki A, Iso H, & Morita Y (2002). Reduced prepulse inhibition in rats with entorhinal cortex lesions. *Behavioural Brain Research*, 134, 201–207. [PubMed: 12191806]
- Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, et al. (2005). Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. *Journal of Neurochemistry*, 93, 105–117. [PubMed: 15773910]
- Gulinello M, Gertner M, Mendoza G, Schoenfeld BP, Oddo S, LaFerla F, et al. (2009). Validation of a 2-day water maze protocol in mice. *Behavioural Brain Research*, 196, 220–227. [PubMed: 18831990]
- Hagner PR, Mazan-Mamczarz K, Dai B, Corl S, Zhao XF, & Gartenhaus RB (2009). Alcohol consumption and decreased risk of non-Hodgkin lymphoma: Role of mTOR dysfunction. *Blood*, 113, 5526. [PubMed: 19293424]
- Hardy J, & Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science*, 297, 353–356. [PubMed: 12130773]
- Hensley K, Gabbita SP, Venkova K, Hristov A, Johnson MF, Eslami P, et al. (2013). A derivative of the brain metabolite lanthionine ketimine improves cognition and diminishes pathology in the 3 × Tg-AD mouse model of Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*, 72, 955–969. [PubMed: 24042198]
- Hensley K, Venkova K, Christov A, Gunning W, & Park J (2011). Collapsin response mediator protein-2: An emerging pathologic feature and therapeutic target for neurodegeneration indications. *Molecular Neurobiology*, 43, 180–191. [PubMed: 21271304]
- Hernandez F (2013). GSK3 and tau: Two convergence points in Alzheimer's disease. *Journal of Alzheimer's disease: JAD*, 33(Suppl. 1), S141–S144. [PubMed: 22710914]
- Hersi M, Irvine B, Gupta P, Gomes J, Birkett N, & Krewski D (2017). Risk factors associated with the onset and progression of Alzheimer's disease: A systematic review of the evidence. *Neurotoxicology*, 61, 143–187. [PubMed: 28363508]
- Hodge CW, Chappelle AM, & Samson HH (1996). Dopamine receptors in the medial prefrontal cortex influence ethanol and sucrose-reinforced responding. *Alcoholism, Clinical and Experimental Research*, 20, 1631–1638.
- Hodge CW, Mehmert KK, Kelley SP, McMahon T, Haywood A, Olive MF, et al. (1999). Supersensitivity to allosteric GABA(A) receptor modulators and alcohol in mice lacking PKCepsilon. *Nature Neuroscience*, 2, 997–1002. [PubMed: 10526339]
- Hoenig K, Hochrein A, Quednow BB, Maier W, & Wagner M (2005). Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder. *Biological Psychiatry*, 57, 1153–1158. [PubMed: 15866555]
- Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, & Morgan D (1999). Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits. *Behavior Genetics*, 29, 177–185. [PubMed: 10547924]
- Holstein SE, Spanos M, & Hodge CW (2011). Adolescent C57BL/6J mice show elevated alcohol intake, but reduced taste aversion, as compared to adult mice: A potential behavioral mechanism for binge drinking. *Alcoholism, Clinical and Experimental Research*, 35, 1842–1851.
- Hooper C, Killick R, & Lovestone S (2008). The GSK3 hypothesis of Alzheimer's disease. *Journal of Neurochemistry*, 104, 1433–1439. [PubMed: 18088381]

- Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. (1996). Correlative memory deficits, A β elevation, and amyloid plaques in transgenic mice. *Science*, 274, 99–103. [PubMed: 8810256]
- Huang HJ, Chen SL, Huang HY, Sun YC, Lee GC, Lee-Chen GJ, et al. (2019). Chronic low dose of AM404 ameliorates the cognitive impairment and pathological features in hyperglycemic 3xTg-AD mice. *Psychopharmacology*, 236, 763–773. [PubMed: 30426182]
- Huang D, Yu M, Yang S, Lou D, Zhou W, Zheng L, et al. (2018). Ethanol alters APP processing and aggravates Alzheimer-associated phenotypes. *Molecular Neurobiology*, 55, 5006–5018. [PubMed: 28799137]
- Huber CM, Yee C, May T, Dhanala A, & Mitchell CS (2018). Cognitive decline in preclinical Alzheimer's disease: Amyloid-beta versus tauopathy. *Journal of Alzheimer's Disease: JAD*, 61, 265–281. [PubMed: 29154274]
- Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, et al. (1999). Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. *Neuron*, 24, 751–762. [PubMed: 10595524]
- Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 14, 535–562.
- Jacobs JF, van der Molen RG, Bossuyt X, & Damoiseaux J (2015). Antigen excess in modern immunoassays: To anticipate on the unexpected. *Autoimmunity Reviews*, 14, 160–167. [PubMed: 25461469]
- Jacobs EH, Williams RJ, & Francis PT (2006). Cyclin-dependent kinase 5, Munc18a and Munc18-interacting protein 1/X11alpha protein up-regulation in Alzheimer's disease. *Neuroscience*, 138, 511–522. [PubMed: 16413130]
- Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. (2003). Mutant presenilins specifically elevate the levels of the 42 residue β -amyloid peptide in vivo: Evidence for augmentation of a 42-specific γ secretase. *Human Molecular Genetics*, 13, 159–170. [PubMed: 14645205]
- Jankowsky JL, & Zheng H (2017). Practical considerations for choosing a mouse model of Alzheimer's disease. *Molecular Neurodegeneration*, 12, 89. [PubMed: 29273078]
- Jensen TMT, Albertsen L, Bartling CRO, Haugaard-Kedstrom LM, & Stromgaard K (2018). Probing the Mint2 protein-protein interaction network relevant to the pathophysiology of Alzheimer's disease. *Chembiochem*. 10.1002/cbic.201800004. (Epub ahead of print).
- Jessen F, et al. (2014). A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 10, 844–852.
- Jin-Jing P (2008). p70 S6 kinase and tau in Alzheimer's disease. *Journal of Alzheimer's Disease: JAD*, 14, 385–392. [PubMed: 18688088]
- Jung CH, Ro S-H, Cao J, Otto NM, & Kim D-H (2010). mTOR regulation of autophagy. *FEBS Letters*, 584, 1287–1295. [PubMed: 20083114]
- Khan UA, Liu L, Provenzano FA, Berman DE, Profaci CP, Sloan R, et al. (2014). Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. *Nature Neuroscience*, 17, 304–311. [PubMed: 24362760]
- King MK, Pardo M, Cheng Y, Downey K, Joje RS, & Beurel E (2014). Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. *Pharmacology & Therapeutics*, 141, 1–12. [PubMed: 23916593]
- Kohl S, Heekeren K, Klosterkotter J, & Kuhn J (2013). Prepulse inhibition in psychiatric disorders—Apart from schizophrenia. *Journal of Psychiatric Research*, 47, 445–452. [PubMed: 23287742]
- Koob GF, & Volkow ND (2010). Neurocircuitry of addiction. *Neuropsychopharmacology*, 35, 217–238. [PubMed: 19710631]
- Kramer A, Green J, Pollard J Jr., & Tugendreich S (2014). Causal analysis approaches in ingenuity pathway analysis. *Bioinformatics*, 30, 523–530. [PubMed: 24336805]
- Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, Perault-Pochat MC, Gil R, et al. (2005). mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models

- and in patients with Alzheimer's disease. *Journal of Neurochemistry*, 94, 215–225. [PubMed: 15953364]
- Lafay-Chebassier C, Perault-Pochat MC, Page G, Rioux Bilan A, Damjanac M, Pain S, et al. (2006). The immunosuppressant rapamycin exacerbates neurotoxicity of Aβ peptide. *Journal of Neuroscience Research*, 84, 1323–1334. [PubMed: 16955484]
- Lalonde R, Dumont M, Staufenbiel M, & Strazielle C (2005). Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. *Behavioural Brain Research*, 157, 91–98. [PubMed: 15617775]
- Lewis B, Garcia CC, Boissoneault J, Price JL, & Nixon SJ (2019). Working memory performance following acute alcohol: Replication and extension of dose by age interactions. *Journal of Studies on Alcohol and Drugs*, 80, 86–95. [PubMed: 30807279]
- Lewis B, Garcia CC, & Nixon SJ (2018). Drinking patterns and adherence to “low-risk” guidelines among community-residing older adults. *Drug and Alcohol Dependence*, 187, 285–291. [PubMed: 29698895]
- Li Q, & Ren J (2007). Chronic alcohol consumption alters mammalian target of rapamycin (mTOR), reduces ribosomal p70s6 kinase and p4E-BP1 levels in mouse cerebral cortex. *Experimental Neurology*, 204, 840–844. [PubMed: 17291499]
- Lithfous S, Dufour A, & Despres O (2013). Spatial navigation in normal aging and the prodromal stage of Alzheimer's disease: Insights from imaging and behavioral studies. *Ageing Research Reviews*, 12, 201–213. [PubMed: 22771718]
- Liu F, Laguesse S, Legastelois R, Morisot N, Ben Hamida S, & Ron D (2017). mTORC1-dependent translation of collapsin response mediator protein-2 drives neuroadaptations underlying excessive alcohol-drinking behaviors. *Molecular Psychiatry*, 22, 89–101. [PubMed: 26952865]
- Llorens-Martin M, Jurado J, Hernandez F, & Avila J (2014). GSK-3β, a pivotal kinase in Alzheimer disease. *Frontiers in Molecular Neuroscience*, 7, 46. [PubMed: 24904272]
- Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, et al. (2013). Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. *The Journal of Clinical Investigation*, 123, 224–235. [PubMed: 23202730]
- Lynn BC, Wang J, Markesbery WR, & Lovell MA (2010). Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer's disease. *Journal of Alzheimer's Disease: JAD*, 19, 325–339. [PubMed: 20061648]
- Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, et al. (2009). Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: Suppression by omega-3 fatty acids and curcumin. *The Journal of Neuroscience*, 29, 9078–9089. [PubMed: 19605645]
- Martins-De-Souza D, Dias-Neto E, Schmitt A, Falkai P, Gormanns P, Maccarrone G, et al. (2010). Proteome analysis of schizophrenia brain tissue. *The World Journal of Biological Psychiatry*, 11, 110–120. [PubMed: 20109112]
- Masurkar AV (2018). Towards a circuit-level understanding of hippocampal CA1 dysfunction in Alzheimer's disease across anatomical axes. *Journal of Alzheimer's disease & Parkinsonism*, 8, pii 412.
- McCool BA, Christian DT, Diaz MR, & Lack AK (2010). Glutamate plasticity in the drunken amygdala: The making of an anxious synapse. *International Review of Neurobiology*, 91, 205–233. [PubMed: 20813244]
- McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. (2011). The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 7, 263–269.
- Mega MS, Cummings JL, Fiorello T, & Gornbein J (1996). The spectrum of behavioral changes in Alzheimer's disease. *Neurology*, 46, 130–135. [PubMed: 8559361]
- Morris RG, Garrud P, Rawlins JN, & O'Keefe J (1982). Place navigation impaired in rats with hippocampal lesions. *Nature*, 297, 681–683. [PubMed: 7088155]

- Moussa MN, Simpson SL, Mayhugh RE, Grata ME, Burdette JH, Porrino LJ, et al. (2014). Long-term moderate alcohol consumption does not exacerbate age-related cognitive decline in healthy, community-dwelling older adults. *Frontiers in Aging Neuroscience*, 6, 341. [PubMed: 25601835]
- Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, et al. (2000). High-level neuronal expression of A β ₁₋₄₂ in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. *The Journal of Neuroscience*, 20, 4050–4058. [PubMed: 10818140]
- Mukamal KJ, Longstreth WT Jr., Mittleman MA, Crum RM, & Siscovick DS (2001). Alcohol consumption and subclinical findings on magnetic resonance imaging of the brain in older adults: The cardiovascular health study. *Stroke*, 32, 1939–1946. [PubMed: 11546878]
- Neasta J, Barak S, Hamida SB, & Ron D (2014). mTOR complex 1: A key player in neuroadaptations induced by drugs of abuse. *Journal of Neurochemistry*, 130, 172–184. [PubMed: 24666346]
- Neasta J, Ben Hamida S, Yowell Q, Carnicella S, & Ron D (2010). Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders. *Proceedings of the National Academy of Sciences of the United States of America*, 107, 20093–20098. [PubMed: 21041654]
- Neasta J, Ben Hamida S, Yowell QV, Carnicella S, & Ron D (2011). AKT signaling pathway in the nucleus accumbens mediates excessive alcohol drinking behaviors. *Biological Psychiatry*, 70, 575–582. [PubMed: 21549353]
- Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, et al. (2018). Phosphorylation of different tau sites during progression of Alzheimer's disease. *Acta Neuropathologica Communications*, 6, 52. [PubMed: 29958544]
- NIAAA. (2017). NIAAA strategic plan 2017–2021. National Institute on Alcohol Abuse and Alcoholism. <https://www.niaaa.nih.gov/strategic-plan>.
- Norambuena A, Wallrabe H, McMahon L, Silva A, Swanson E, Khan SS, et al. (2017). mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 13, 152–167.
- Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. (2006). Intraneuronal β -amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. *The Journal of Neuroscience*, 26, 10129–10140. [PubMed: 17021169]
- Oddo S (2012). The role of mTOR signaling in Alzheimer disease. *Frontiers in Bioscience (Scholar Edition)*, 4, 941–952. [PubMed: 22202101]
- Oddo S, Caccamo A, Kitazawa M, Tseng BP, & LaFerla FM (2003). Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. *Neurobiology of Aging*, 24, 1063–1070. [PubMed: 14643377]
- Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, et al. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular A β and synaptic dysfunction. *Neuron*, 39, 409–421. [PubMed: 12895417]
- Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, et al. (2006). Temporal profile of amyloid-beta (A β) oligomerization in an in vivo model of Alzheimer disease. A link between A β and tau pathology. *The Journal of Biological Chemistry*, 281, 1599–1604. [PubMed: 16282321]
- Ogata H, Ogato F, Mendelson JH, & Mello NK (1972). A comparison of techniques to induce alcohol dependence and tolerance in the mouse. *The Journal of Pharmacology and Experimental Therapeutics*, 180, 216–230. [PubMed: 5062298]
- Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R, et al. (2007). BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. *Neurobiology of Disease*, 26, 134–145. [PubMed: 17258906]
- Olive MF, & Hodge CW (2000). Co-localization of PKC ϵ with various GABA (A) receptor subunits in the mouse limbic system. *Neuroreport*, 11, 683–687. [PubMed: 10757500]
- Pabst S, Margittai M, Vainius D, Langen R, Jahn R, & Fasshauer D (2002). Rapid and selective binding to the synaptic SNARE complex suggests a modulatory role of complexins in neuroexocytosis. *The Journal of Biological Chemistry*, 277, 7838–7848. [PubMed: 11751907]

- Pai MC, & Jacobs WJ (2004). Topographical disorientation in community-residing patients with Alzheimer's disease. *International Journal of Geriatric Psychiatry*, 19, 250–255. [PubMed: 15027040]
- Palmer AM (2002). Pharmacotherapy for Alzheimer's disease: Progress and prospects. *Trends in Pharmacological Sciences*, 23, 426–433. [PubMed: 12237155]
- Palmer K, Lupo F, Perri R, Salamone G, Fadda L, Caltagirone C, et al. (2011). Predicting disease progression in Alzheimer's disease: The role of neuropsychiatric syndromes on functional and cognitive decline. *Journal of Alzheimer's Disease: JAD*, 24, 35–45. [PubMed: 21157019]
- Pandey SC, Zhang H, Ugale R, Prakash A, Xu T, & Misra K (2008). Effector immediate-early gene arc in the amygdala plays a critical role in alcoholism. *The Journal of Neuroscience*, 28, 2589. [PubMed: 18322102]
- Pei J-J, & Hugon J (2008). mTOR-dependent signalling in Alzheimer's disease. *Journal of Cellular and Molecular Medicine*, 12, 2525–2532.
- Phillips RG, & LeDoux JE (1992). Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. *Behavioral Neuroscience*, 106, 274–285. [PubMed: 1590953]
- Piazza-Gardner AK, Gaffud TJ, & Barry AE (2013). The impact of alcohol on Alzheimer's disease: A systematic review. *Aging & Mental Health*, 17, 133–146. [PubMed: 23171229]
- Pietropaolo S, Feldon J, & Yee BK (2014). Environmental enrichment eliminates the anxiety phenotypes in a triple transgenic mouse model of Alzheimer's disease. *Cognitive, Affective, & Behavioral Neuroscience*, 14, 996–1008.
- Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA, Harrington K, et al. (2015). Amyloid-beta, anxiety, and cognitive decline in preclinical Alzheimer disease: A multicenter, prospective cohort study. *JAMA Psychiatry*, 72, 284–291. [PubMed: 25629787]
- Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al. (2006). A β 42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. *EMBO Reports*, 7, 940–946. [PubMed: 16906128]
- Raskin J, Cummings J, Hardy J, Schuh K, & Dean RA (2015). Neurobiology of Alzheimer's disease: Integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. *Current Alzheimer Research*, 12, 712–722. [PubMed: 26412218]
- Rivera I, Capone R, Cauvi DM, Arispe N, & De Maio A (2018). Modulation of Alzheimer's amyloid beta peptide oligomerization and toxicity by extracellular Hsp70. *Cell Stress & Chaperones*, 23, 269–279. [PubMed: 28956268]
- Robinson RA, Amin B, & Guest PC (2017). Multiplexing biomarker methods, proteomics and considerations for Alzheimer's disease. *Advances in Experimental Medicine and Biology*, 974, 21–48. [PubMed: 28353223]
- Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, et al. (2007). Neuroprotective effects of regulators of the glycogen synthase kinase-3 β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. *The Journal of Neuroscience*, 27, 1981–1991. [PubMed: 17314294]
- Romano A, Pace L, Tempesta B, Lavecchia AM, Macheda T, Bedse G, et al. (2014). Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer's disease. *The International Journal of Neuropsychopharmacology*, 18, pyu020.
- Ruitenbergh A, van Swieten JC, Wittman JC, Mehta KM, van Duijn CM, Hofman A, et al. (2002). Alcohol consumption and risk of dementia: The Rotterdam study. *The Lancet*, 359, 281–286.
- Sacks JJ, Gonzales KR, Bouchery EE, Tomedi LE, & Brewer RD (2015). 2010 national and state costs of excessive alcohol consumption. *American Journal of Preventive Medicine*, 49, e73–e79. [PubMed: 26477807]
- Salling MC, Faccidomo SP, Li C, Psilos K, Galunas C, Spanos M, et al. (2016). Moderate alcohol drinking and the amygdala proteome: Identification and validation of calcium/calmodulin dependent kinase II and AMPA receptor activity as novel molecular mechanisms of the positive reinforcing effects of alcohol. *Biological Psychiatry*, 79, 430–442. [PubMed: 25579851]
- Salling MC, Hodge CJ, Psilos KE, Eastman VR, Faccidomo SP, & Hodge CW (2017). Cue-induced reinstatement of alcohol-seeking behavior is associated with increased CaMKII T286

phosphorylation in the reward pathway of mice. *Pharmacology, Biochemistry, and Behavior*, 163, 20–29.

- Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, et al. (2005). Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. *The Journal of Neuroscience*, 25, 6755–6764. [PubMed: 16033885]
- Schroeder JP, Olive F, Koenig H, & Hodge CW (2003). Intra-amygdala infusion of the NPY Y1 receptor antagonist BIBP 3226 attenuates operant ethanol self-administration. *Alcoholism, Clinical and Experimental Research*, 27, 1884–1891.
- Schroeder JP, Spanos M, Stevenson JR, Besheer J, Salling M, & Hodge CW (2008). Cue-induced reinstatement of alcohol-seeking behavior is associated with increased ERK1/2 phosphorylation in specific limbic brain regions: Blockade by the mGluR5 antagonist MPEP. *Neuropharmacology*, 55, 546–554. [PubMed: 18619984]
- Sereno L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sanchez MB, Gich I, et al. (2009). A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. *Neurobiology of Disease*, 35, 359–367. [PubMed: 19523516]
- Siman R, Cocca R, & Dong Y (2015). The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy. *PLoS One*, 10, e0142340. [PubMed: 26540269]
- Soutar MP, Thornhill P, Cole AR, & Sutherland C (2009). Increased CRMP2 phosphorylation is observed in Alzheimer's disease; does this tell us anything about disease development? *Current Alzheimer Research*, 6, 269–278. [PubMed: 19519308]
- Spanos M, Besheer J, & Hodge CW (2012). Increased sensitivity to alcohol induced changes in ERK Map kinase phosphorylation and memory disruption in adolescent as compared to adult C57BL/6J mice. *Behavioural Brain Research*, 230, 158–166. [PubMed: 22348893]
- Sperling RA, et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 7, 280–292.
- Squeglia LM, Boissoneault J, Van Skike CE, Nixon SJ, & Matthews DB (2014). Age-related effects of alcohol from adolescent, adult, and aged populations using human and animal models. *Alcoholism, Clinical and Experimental Research*, 38, 2509–2516.
- Stevenson JR, Schroeder JP, Nixon K, Besheer J, Crews FT, & Hodge CW (2009). Abstinence following alcohol drinking produces depression-like behavior and reduced hippocampal neurogenesis in mice. *Neuropsychopharmacology*, 34, 1209–1222. [PubMed: 18563059]
- Stover KR, Campbell MA, Van Winssen CM, & Brown RE (2015a). Early detection of cognitive deficits in the 3xTg-AD mouse model of Alzheimer's disease. *Behavioural Brain Research*, 289, 29–38. [PubMed: 25896362]
- Stover KR, Campbell MA, Van Winssen CM, & Brown RE (2015b). Analysis of motor function in 6-month-old male and female 3xTg-AD mice. *Behavioural Brain Research*, 281, 16–23. [PubMed: 25486177]
- Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold K-H, Mistl C, Rothacher S, et al. (1997). Two amyloid precursor protein transgenic mouse models with Alzheimerdisease-likepathology. *Proceedings of the National Academy of Sciences of the United States of America*, 94, 13287–13292. [PubMed: 9371838]
- Su KY, Chien WL, Fu WM, Yu IS, Huang HP, Huang PH, et al. (2007). Mice deficient in collapsin response mediator protein-1 exhibit impaired long-term potentiation and impaired spatial learning and memory. *The Journal of Neuroscience*, 27, 2513–2524. [PubMed: 17344389]
- Sudhof TC (2013). Neurotransmitter release: The last millisecond in the life of a synaptic vesicle. *Neuron*, 80, 675–690. [PubMed: 24183019]
- Swordlow NR, Geyer MA, & Braff DL (2001). Neural circuit regulation of prepulse inhibition of startle in the rat: Current knowledge and future challenges. *Psychopharmacology*, 156, 194–215. [PubMed: 11549223]

- Takano M, Yamashita T, Nagano K, Otani M, Maekura K, Kamada H, et al. (2013). Proteomic analysis of the hippocampus in Alzheimer's disease model mice by using two-dimensional fluorescence difference in gel electrophoresis. *Neuroscience Letters*, 534, 85–89. [PubMed: 23276639]
- Tang J, Maximov A, Shin OH, Dai H, Rizo J, & Sudhof TC (2006). A complexin/synaptotagmin 1 switch controls fast synaptic vesicle exocytosis. *Cell*, 126, 1175–1187. [PubMed: 16990140]
- Taylor CA, Greenlund SF, McGuire LC, Lu H, & Croft JB (2017). Deaths from Alzheimer's disease—United States, 1999–2014. *MMWR. Morbidity and Mortality Weekly Report*, 66, 521–526. [PubMed: 28542120]
- Tenreiro S, Eckermann K, & Outeiro TF (2014). Protein phosphorylation in neurodegeneration: Friend or foe? *Frontiers in Molecular Neuroscience*, 7, 42. [PubMed: 24860424]
- Thomas VS, & Rockwood KJ (2001). Alcohol abuse, cognitive impairment, and mortality among older people. *Journal of the American Geriatrics Society*, 49, 415–420. [PubMed: 11347785]
- Topiwala A, Allan CL, Valkanova V, Zsoldos E, Filippini N, Sexton C, et al. (2017). Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: Longitudinal cohort study. *BMJ*, 357, j2353. [PubMed: 28588063]
- Tramutola A, Triplett JC, Di Domenico F, Niedowicz DM, Murphy MP, Coccia R, et al. (2015). Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): Analysis of brain from subjects with pre-clinical AD, amnesic mild cognitive impairment and late-stage AD. *Journal of Neurochemistry*, 133, 739–749. [PubMed: 25645581]
- Truelsen T, Thudium D, Gronbaek M, & Copenhagen City Heart Study. (2002). Amount and type of alcohol and risk of dementia: The Copenhagen City Heart Study. *Neurology*, 59, 1313–1319. [PubMed: 12427876]
- Ueki A, Goto K, Sato N, Iso H, & Morita Y (2006). Prepulse inhibition of acoustic startle response in mild cognitive impairment and mild dementia of Alzheimer type. *Psychiatry and Clinical Neurosciences*, 60, 55–62. [PubMed: 16472359]
- Ueno S, Harris RA, Messing RO, Sanchez-Perez AM, Hodge CW, McMahon T, et al. (2001). Alcohol actions on GABA(A) receptors: From protein structure to mouse behavior. *Alcoholism, Clinical and Experimental Research*, 25, 76S–81S.
- van der Vaart A, Meng X, Bowers MS, Batman AM, Aliev F, Farris SP, et al. (2018). Glycogen synthase kinase 3 beta regulates ethanol consumption and is a risk factor for alcohol dependence. *Neuropsychopharmacology*, 43, 2521–2531. [PubMed: 30188517]
- Velazquez R, Tran A, Ishimwe E, Denner L, Dave N, Oddo S, et al. (2017). Central insulin dysregulation and energy dyshomeostasis in two mouse models of Alzheimer's disease. *Neurobiology of Aging*, 58, 1–13. [PubMed: 28688899]
- Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. (2013). Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. *The Lancet. Neurology*, 12, 357–367. [PubMed: 23477989]
- Wang C, Yu J-T, Miao D, Wu Z-C, Tan M-S, & Tan L (2014). Targeting the mTOR signaling network for Alzheimer's disease therapy. *Molecular Neurobiology*, 49, 120–135. [PubMed: 23853042]
- Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, & Van Eldik LJ (2014). Using mice to model Alzheimer's dementia: An overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. *Frontiers in Genetics*, 5, 88. [PubMed: 24795750]
- Weyerer S, Schaufele M, Wiese B, Maier W, Tebarth F, van den Bussche H, et al. (2011). Current alcohol consumption and its relationship to incident dementia: Results from a 3-year follow-up study among primary care attenders aged 75 years and older. *Age and Ageing*, 40, 456–463. [PubMed: 21367764]
- Whitwell JL (2010). Progression of atrophy in Alzheimer's disease and related disorders. *Neurotoxicity Research*, 18, 339–346. [PubMed: 20352396]
- WHO. (2018). Global status report on alcohol and health. Geneva: WHO Press.
- Wolen AR, Phillips CA, Langston MA, Putman AH, Vorster PJ, Bruce NA, et al. (2012). Genetic dissection of acute ethanol responsive gene networks in prefrontal cortex: Functional and mechanistic implications. *PLoS One*, 7, e33575. [PubMed: 22511924]
- Woodgett JR (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. *The EMBO Journal*, 9, 2431–2438. [PubMed: 2164470]

- Xiao NA, Zhang J, Zhou M, Wei Z, Wu XL, Dai XM, et al. (2015). Reduction of glucose metabolism in olfactory bulb is an earlier Alzheimer's disease-related biomarker in 5XFAD mice. *Chinese Medical Journal*, 128, 2220–2227. [PubMed: 26265617]
- Xu YY, Bhavani K, Wands JR, & de la Monte SM (1995). Ethanol inhibits insulin receptor substrate-1 tyrosine phosphorylation and insulin-stimulated neuronal thread protein gene expression. *Biochemical Journal*, 310(Pt. 1), 125–132. [PubMed: 7646434]
- Yoshida H, Watanabe A, & Ihara Y (1998). Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer's disease. *The Journal of Biological Chemistry*, 273, 9761–9768. [PubMed: 9545313]
- Yoshiyama Y, Higuchi M, Zhang B, Huang S-M, Iwata N, Saido Takaomi C, et al. (2007). Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. *Neuron*, 53, 337–351. [PubMed: 17270732]
- Yu JS, & Cui W (2016). Proliferation, survival and metabolism: The role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. *Development*, 143, 3050–3060. [PubMed: 27578176]
- Zilkens RR, Bruce DG, Duke J, Spilsbury K, & Semmens JB (2014). Severe psychiatric disorders in mid-life and risk of dementia in late-life (age 65–84 years): A population based case-control study. *Current Alzheimer Research*, 11, 681–693. [PubMed: 25115541]

Fig. 1.

Bioinformatic analysis of alcohol-sensitive protein networks in PFC and amygdala identified major mechanisms of AD (MAPT, APP, and PSEN1) as the statistically most likely upstream regulators. (A) Illustration of mouse home-cage drinking method and sample brain regions showing anatomical location of tissue punches. (B) Representative 2D-DIGE gels from each experiment. (C) Results of IPA Upstream Regulator Analysis that identified Alzheimer's disease mechanisms as top regulators of alcohol-sensitive protein networks. (D) Alcohol-sensitive proteins detected in each brain region that are known to be downstream of MAPT, APP, and PSEN1. *P* values indicate significant overlap between AD regulator protein and alcohol-sensitive Alzheimer's-linked molecules. Arrows indicate increase (↑) or decrease (↓) in expression after alcohol drinking. Data are shown as fold change representing the mean of four replicate gels. Proteins were included only if significantly changed in all four gels.

Fig. 2.
(A) Alzheimer’s disease progression showing mouse brain regional involvement and clinical symptoms as a function severity. (B) Graphic representation of the overall hypothesis of the present study: alcohol use (red line) exacerbates the onset (leftward time-dependent shift in age of onset) and magnitude (upward shift in degree) of AD-like pathology (black line).

Fig. 3.

Experimental timeline. Mice drank solutions (alcohol or saccharin) starting at 3 months of age for 4 months. Behavioral testing occurred after experimental solutions were removed. Behavioral testing occurred in the following sequence with a minimum of 1 day in between each test: Open field locomotion, rotarod, Morris Water Maze, prepulse inhibition, fear conditioning. Brains were collected at 8 months of age, 10 days after the final behavioral test.

Fig. 4.

No differences in alcohol or saccharin intake or motor function in 3xTg-AD mice as compared to WT controls. (A) Average alcohol intake (g/kg) and preference (% total fluid) from the 4-month access period plotted as a function of genotype. (B) Average saccharin intake (mL) and preference (% total fluid) plotted as a function of genotype. (C) Average body weight (g) of WT and 3xTg-AD mice at 10 weeks of age (male and female combined). (D) Spontaneous locomotor behavior and habituation to an unfamiliar environment. Mice were placed in locomotor activity chambers, and distance traveled was measured during a single session. (E) Rotarod performance by 3xTg-AD and WT mice expressed as average latency to fall (s) over three trials. Data are shown as mean SEM. No statistically significant differences were detected between genotypes or alcohol/saccharin condition.

Fig. 5.

Alcohol drinking-induced behavioral deficits in 3xTg-AD mice. (A, left) Average escape latency (s) plotted as a function of trial during Morris Water Maze acquisition. * indicates significant main effect between genotypes over all trials. (A, right) Percentage of time (s) spent in the quadrant of the Morris Water Maze that previously contained the escape platform. * indicates significant difference between alcohol vs saccharin exposed 3xTg-AD mice, $P < 0.05$. (B) Average prepulse inhibition (%) plotted as a function of stimulus intensity (dB). * indicates statistically significant main effect between 3xTg-AD mice that consumed alcohol vs saccharin. (C, left) Cued fear response plotted as average freezing (%)

control seconds) as a function of genotype and alcohol intake condition. * indicates significant difference between 3xTg-AD mice that consumed alcohol vs saccharin, $P < 0.05$. (C, right) Context-dependent fear response plotted as freezing (% control) as a function of genotype and treatment conditions. Abbreviations: Saccharin (Sacc), Alcohol (Alc).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Fig. 6.

AD biomarker protein expression in specific brain regions of 3xTg-AD mice at 1-month post alcohol drinking. The title above each graph shows brain region and the AT(N) rubric for biomarker interpretation (see Table 2). (A-D, left) Mean $\pm$ SEM A β (42/40) ratio. (A-D, right) Total Tau protein expressed as mean $\pm$ SEM background corrected Median Fluorescence Intensity (MFI). Measures are plotted as a function of drinking history (S—saccharin; A—alcohol). * $P < 0.05$; ** $P < 0.01$, A vs S, t -test. WT control wells exhibited expression at background levels (data not shown).

Fig. 7. pTau-Ser199/202 immunoreactivity (IR) in WT and 3xTg-AD mice 1-month post alcohol or saccharin drinking. (A) Coronal sections of dorsal hippocampus showing prominent IR in neuronal cell bodies and projections of CA1 only in 3xTg-AD mice with upregulation post alcohol (EtOH). (B) Basolateral amygdala (BLA) sections showing no alcohol-induced difference in pTau-Ser199/202 IR. Images acquired on Olympus BX51 microscope at 10× magnification.

Table 1

Examples of transgenic mouse models of AD expressing human APP, APP + PS1, Tau, and APP + PS1 + Tau.

Mouse model	APP	PS1	Tau	Transgene	References
PDAPP	×			huAPP770 (Ind) minigene (cDNA + introns 6–8)	Games et al. (1995)
Tg2576	×			huAPP695 (Swe)	Hsiao et al. (1996)
APP23	×			huAPP751 (Swe)	Sturchler-Pierrat et al. (1997)
J20	×			huAPP770 (Swe/Ind) minigene (cDNA + introns 6–8)	Mucke et al. (2000)
APP/PS1	×	×		mo/huAPP695 (Swe); Tg huPSEN1 (AE9)	Jankowsky et al. (2003)
APP + PS1	×	×		huAPP695 (Swe); huPSEN1 (L166P)	Holcomb et al. (1999), Radde et al. (2006)
5×FAD	×	×		huAPP695 (Swe/Flo/Lon); huPSEN1 (M146 L/L286 V)	Oakley et al. (2006)
Tau Tg Line 43			×	huMAPT3R0N (wt)	Ishihara et al. (1999)
PS19			×	huMAPT4RIN (P301S)	Yoshiyama et al. (2007)
3xTg-AD	×	×	×	huAPP695 (Swe); MAPT4R0N (P301L); Psen1 M146V knock-in	Oddo, Caccamo, Kitazawa, Tseng, and LaFerla (2003)

Table 2

NIAA-AA Research Framework showing AT(N) biomarker groupings associated with disease categories (top) and AT(N) definitions (bottom).

AT(N) biomarker grouping	Disease category
A–T–(N)–	Normal AD biomarkers
A + T–(N)–	Alzheimer's pathologic change
A + T+(N)–	Alzheimer's disease
A + T+(N)+	Alzheimer's disease
A + T–(N)+	Alzheimer's and concomitant non-AD pathology
A–T+(N)–	Non-AD pathology
A–T–(N)+	Non-AD pathology
A–T+(N)+	Non-AD pathology
<i>AT(N) definitions</i>	
A	Aggregated A β (plaques); A β 42 or A β 42/40 ratio elevated in brain (reduced in CSF)
T	Aggregated Tau (tangles); elevated pTau
N	Neurodegeneration; elevated total Tau

+ indicates presence, – indicates absence of change in biomarker.

Adapted from Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, 14, 535–562.

Table 3

mTOR/Akt phosphoprotein cell signaling in 3xTg-AD mice.

Protein	Phosphorylation site	mPFC	PFC	Acb	AMY	MHPC	LHPC	CA1	LEC	MEC
Akt/PKB	(Ser473)	111.3	91.4	90.7	95.7	113.5	103.2	81.7	68.6	81.8
ERK 1/2	(Thr185/Tyr187)	101.9	80.3	91.4	69.0*	109.6	74.3	93.0	74.0	64.7
GSK3 α	(Ser21)	72.6	71.1	91.4	97.5	82.2	84.9	122.8	52.4	60.5*
GSK3 β	(Ser9)	130.6	99.4	90.6	96.8	114.9	91.7	83.4	101.2	109.6
IGF1R	(Tyr1135/1136)	89.7	86.2	91.5	86.7	79.7	68.2	104.7	59.7*	69.4*
IR	(Tyr1162/1163)	105.6	113.2	81.9	86.8	98.8	91.1	92.5	54.4*	80.4
IRS1	(Ser636)	94.0	88.3	82.7	106.4	80.0	66.3*	88.2	56.4	64.3*
mTOR	(Ser2448)	102.0	86.6	82.8	74.0	84.1	85.9	76.3*	68.5	82.2
p70S6K	(Thr389/412)	74.7	117.1	50.7	87.7	65.1	49.4*	142.0	62.0	59.7
PTEN	(Ser380)	104.6	106.1	89.1	94.7	108.3	113.6	80.3*	72.9*	109.1
RPS6	(Ser235/236)	96.1	93.1	81.3	93.9	87.7	83.7	103.5	60.2	73.7*
TSC2	(Ser939)	104.8	117.0	99.7	119.3	115.4	78.6	81.3	94.1	101.4

This table shows the percent change in relative protein expression of 3xTg-AD alcohol drinking mice compared to saccharin drinking mice at 1-month post alcohol (8-months old). Relative change calculated using β -Tubulin as loading control. All analytes and brain regions were treated as independent samples for analysis. Shaded boxes with * indicate $P < 0.05$; for one-tailed, t -test.

Abbreviations: protein kinase B (Akt/PKB), mitogen-activated protein kinase/extracellular signal-regulated kinases pathway (ERK 1/2), glycogen synthase kinase 3 α (GSK3 α), glycogen synthase kinase 3 β (GSK3 β), insulin-like growth factor 1 receptor (IGF1R), insulin receptor (IR), insulin receptor substrate 1 (IRS1), mammalian target of rapamycin (mTOR), ribosomal protein S6 kinase β -1 (p70S6K), phosphatase and tensin homolog (PTEN), ribosomal protein S6 (RPS6), mTOR complex 2 (TSC2).